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1. Introduction 
Formation of haemostatic plugs after the vascular injury is a critical survival 
response for the prevention of excessive blood loss (Westrick et al., 2007). The 
coagulation process that leads to haemostasis involves a complex cascade of reactions. 
This includes conversion of prothrombin to thrombin which in turn converts soluble 
fibrinogen to an insoluble fibrin network, which further forms a complex with platelets 
leading to a stable thrombus formation. Inherited or acquired disparity in the coagulation 
process leads to an increased risk of thrombosis. There are two distinctive forms of 
thrombosis, venous thrombosis and arterial thrombosis, each of them can be represented 
by several subcategories based on the occurrence sites (e.g. renal, jugular vein, cerebral 
venous, carotid artery, etc.). Thrombotic complications and the associated vascular 
diseases are the leading cause of mortality and morbidity worldwide. Heart attack and 
stroke are the two major consequences. These are typically acute events and are primarily 
caused by thrombus formation that prevents blood flow to regions of the heart or brain.  
1.1. Haemostasis 
Blood is the transport system that brings nutrients and oxygen to support living 
cells and simultaneously facilitates the scavenging of carbon dioxide and other waste 
products from the body.  If the pressurized circulatory system gets injured, a cascade of 
reactions is initiated to seal the system. This prevents the loss of blood as well as blocks 
the entrance of foreign organisms. Thus, blood borne cells and plasmatic proteins play an 
important defensive role in our body. This process is called haemostasis and it acts 
quickly and effectively to prevent excessive bleeding. This process depends on an 
intricate series of events involving platelets, leucocytes, coagulation proteins and a host 
of other components. Injury to a blood vessel triggers the coagulation cascade that is 
divided into the intrinsic, the extrinsic and the common pathway. The endothelium 
controls the pro and anticoagulant factors to limit haemostasis at the site of vascular 
injury (Golan, 2007).   
1.2. Platelets in primary haemostasis 
Vascular injury exposes the collagen and vWF (von willebrand factor) in the 
vessel wall to the circulatory system. Adherence of platelets to the extracellular matrix, 
especially collagen, is the initial step in primary haemostasis. Activated platelet 
monolayer is formed on the surface (rolling, adhering and spreading) of the exposed 
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collagen matrix when it comes in contact with vWF, secreted by the endothelial cells 
(Brass, 2003). 
Figure 1.1: Primary platelet plug: activation of platelet and platelet adhesion: vWF interaction with 
GPIb leads to platelet activation. This inturn stimulates the downstream pathway to release TXA2. TXA2 
and PGI2 must be balanced in order to maintain haemostasis. vWF: von Willebrand factor; TXA2: 
Thromboxane A2; PGI2: Prostaglandin I2; NO: Nitric oxide; SMC: Smooth muscle cells; GPIb: 
Glycoprotein Ib; PLA2: Phospholipase A2; COX: Cyclooxygenase.    
The initial platelet adhesion is mediated by the interaction between Glycoprotein 
(GP)Ib/V/IX receptor complexes on the surface of platelets with vWF as well as 
Glycoprotein (GP)VI and GPIb with collagen, at the sites of vascular injury. Under 
normal conditions, soluble as well as normal endothelial vWF does not interact 
significantly with GPIb/V/IX complexes. Interestingly, at the sites of injury, vWF 
released from the damaged endothelium is immobilized on the collagen surface, which 
acts as a strong adhesive substrate for platelet adhesion thereby leading to its activation 
(Jennings, 2009). This in turn initiates phosphorylation reaction within the platelets 
which leads to the further release of platelet granules. This also leads to activation of the 
platelet membrane phospholipase A2 to form arachidonic acid via platelet phospholipids. 
This arachidonic acid is further converted to thromboxane A2 (TXA2), with the help of 
cyclooxygenase (COX) which propagates further platelet activation and vasoconstriction 
by stimulating, the granule release reaction (Fig. 1.1). There are two types of granules 
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released by platelets namely delta (δ) granules (serotonin, adenosine diphosphate (ADP) 
and Ca2+) and alpha (α) granules (coagulation factors, fibrinogen and platelet derived 
growth factors). These platelet derived factors further activate other platelets eventually a 
platelet plug is formed (Kottke-Marchant, 2010). TXA2 and ADP play a potential role in  
Figure 1.2: Primary platelet plug and receptor complexes:  Receptor complexes differ based on the type 
of interactions involved. During the platelet adhesion process, vWF interacts through GPIb receptor with 
platelets. Whereas during the platelet aggregation process, platelets aggregate via GPIIb-IIIa receptors 
mediated by fibrinogen. GPIIb-IIIa: Glycoprotein IIb-IIIa; SMC: Smooth muscle cells; GPIb: 
Glycoprotein Ib.  
leading to platelet aggregation. Platelets aggregate to each other via a binding molecule, 
fibrinogen, which has multiple binding sites for functional GPIIb-IIIa (Suehiro et al., 
1996)(Fig. 1.2). However, this primary haemostatic platelet plug is unstable, the stability 
being inversely proportional to the diameter, internal flow rate and flow pressure of the 
vessel (Reininger et al., 2006). 
1.3. Secondary haemostasis  
Secondary haemostasis is also described as the coagulation cascade. The main 
function of this cascade is to stabilize the primary platelet plug via cross-linked fibrin via 
a process that involves a sequence of enzymatic reactions (Fig. 1.3). Firstly, the 
circulating inactive proenzymes, which are synthesized by the liver, are proteolytically 
cleaved in order to become active. These activated factors lead to a chain of catalytic 
activation of other downstream factors. As a result of this catalytic activation, large 
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amounts of fibrin are formed in a short period of time at the injured sites. Secondly, the 
negatively charged phospholipids, such as phosphatidylserine (PS), help to form 
complexes of zymogens, cofactors and activators on the platelet surface. Normally, PS is 
present in the inner leaflet of the plasma membrane but due to cell death or other active 
processes they  translocate to the outer leaflet of the membrane. Calcium is also required 
for the enzyme, substrate and co-factor to assemble in a specific conformation for the 
activation of subsequent proenzymatic coagulation factors by proteolytic cleavage. The 
coagulation cascade is divided into two major pathways namely intrinsic pathway and 
extrinsic pathway. The extrinsic pathway is considered to be physiologically more 
important pathway for the initiation of coagulation in vivo (Dahlback, 2000; Mackman et 
al., 2007) as it leads to a faster activation of factor VII via tissue factor (Mann et al., 
1998) thereby forming a complex which further activates Factor X. 
 
Figure 1.3: Secondary platelet plug: Activation of coagulation cascade is the primary step in the 
secondary platelet plug formation. Activation of intrinsic (contact factors) and extrinsic (tissue factors) 
pathways play a major role in stable fibrin cross-links formation. TF: Tissue factor; TSF: Tissue fibrin 
stabilizing factor; SMC: Smooth muscle cells. 
Factor X can be however activated by both intrinsic and extrinsic pathways (Fig. 
1.3). The intrinsic pathway involves activation of factor XII which undergoes auto-
activation to form factor XIIa on a negatively charged surface. However, charged 
surfaces, and the developing thrombus can also activate the intrinsic pathway in  vivo 
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(Renne et al., 2005; Schmaier and McCrae, 2007). This activated factor XII activates 
factor XI which leads to activation of factor IX which in the presence of factor VIII and 
calcium activates factor X thereby forming Xa. This activated factor Xa further forms a 
complex with factor V in the presence calcium leading to the proteolytic cleavage of 
factor II (Prothrombin) to factor IIa (Thrombin) (Lane et al., 2005). In the pathology of 
thrombosis, thrombin plays several roles, which includes catalytic promotion of the clot 
cascades (factors V and VIII activation), fibrin formation, and activation of factor XIII. 
Most importantly, it acts as a strong activator of platelets, causing the release of granules, 
platelet derived microparticles release and also platelet aggregation. This effect of 
thrombin is mediated through a series of G protein-coupled protease-activated receptors 
(PARs)(Martorell et al., 2008). Activation of these receptors on endothelial cells leads to 
the release of nitric oxide (NO), PGI2, fibrinolytic substances (uPA and tPA) and PAI-1 at 
the site of vessel injury(Verhamme and Hoylaerts, 2006). 
1.4. Regulation of haemostasis  
The endothelium initiates four major mechanisms to maintain constant blood flow 
in the systemic circulation. Firstly, endothelial secretions of NO, prostacyclin (PGI2) and 
ADP dephospatase inhibits activated platelets. Secondly, activation of AT-III via 
endothelial-heparan sulphate leads to the formation of a complex, which inactivates 
thrombin as well as Xa and IXa.  In the third mechanism the endothelial cell surface 
thrombomodulin blocks the coagulation cascade via thrombomodulin-protein C complex. 
Protein C and S are vitamin K dependent proteins that slow down the coagulation 
pathway by cleavage and inactivation of FVa and FVIIIa (Dahlback, 1995; Kottke-
Marchant and Comp, 2002; Lane et al., 2005). 
In addition to the activation protein C, the TM/Thrombin complex also activates 
thrombin activatable fibrinolysis inhibitor (TAFI), which regulates fibrin degradation 
(Myles et al., 2003). Lastly, secretion of plasminogen activators (tPA and uPA) activate 
the fibrinolytic pathway. These plasminogen activators convert the plasminogen into 
plasmin to degrade the fibrin cross-links to fibrin degradation products (FDP). When the 
local concentrations of thrombin and inflammatory cytokines (IL-1 and TNF α) are 
increased, endothelial cells release plasminogen activator inhibitor (PAI), which inhibits 
tPA, leading to less activation of plasminogen (Fig. 1.4). 
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Figure 1.4: Normal defense mechanism to prevent clotting in the circulatory system: Four major 
functions are involved in platelet inactivation. (i) release of NO, PGI2 an ADP dephospatase (ii) activation 
of AT-III via Heparan sulphate,(iii) protein C activation via thrombomodulant and (iv) activation of 
fibrinolysis pathway. ADP: Adenosine 5 diphosphatase; uPA: Urokinase plasminogen activator; tPA: 
Tissue plasminogen activator; FDP: Fibrin degradation product; PGI2: Prostaglandin I2; NO: Nitric 
oxide; AT III:Anti-thrombin III; SMC: Smooth muscle cells; PLG: Plasminogen. 
1.5. Tissue factor pathway inhibitor  
TFPI is an endogenous protein (40-55 kDa), which is a specific anticoagulant 
expressed by endothelial cells, vascular smooth muscle cells, platelets, 
monocytes/macrophages and cardiac myocytes (Bajaj et al., 1990; Caplice et al., 1998; 
Maroney et al., 2007; Novotny et al., 1988; Novotny et al., 1991; van der Logt et al., 
1994; Werling et al., 1993) As its name implies, it limits the action of tissue factor (TF). 
Three isoforms of TFPI exists in mice (α, β and γ) among which TFPIβ is the most 
predominant (Maroney et al., 2008). The coagulation cascade is initiated when activated 
VIIa complex along with TF is exposed or activated at the site of injury. This complex 
catalytically further activates factor X. TFPI inhibits VIIa/TF via two-step process. 
Firstly, it interacts with activated factor Xa forming TFPI/Xa complex which in turn 
interacts with the VIIa/TF complex through second kunitz domain of TFPI leading to 
formation of quaternary complex. This quaternary complex inactivates the factor VIIa:TF 
mediated activation of factor X.  TFPI may also down regulate coagulation cascade by 
internalizing cell surface TF/VIIa complexes.  
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1.6. Fibrinolysis 
The fibrinolytic system is responsible for the degradation of fibrin clots. This 
leads to restoration of blood flow in the obstructed vessels. Plasminogen is the central 
factor of fibrinolysis system, which is activated by urokinase plasminogen 
 activator (uPA) or tissue plasminogen activator (tPA) to plasmin (Fig. 1.6). This 
activated plasmin is responsible for the degradation of fibrin into fibrin degradable 
products (FDP). Two major inhibitors PAI-1 (Loskutoff et al., 1983) and α2-antiplasmin 
(Collen, 1976; Moroi and Aoki, 1976; Mullertz and Clemmensen, 1976), play a vital role 
in the fibrinolytic system. uPA is also believed to be involved in the cell migration, cell 
invasion and metastasis (Carmeliet and Collen, 1996). 
 
Figure 1.5: Fibrinolytic system: Fibrinolysis system also regulates coagulation by generation of plasmin, 
which dissolves fibrin clots. Fibrinolysis system is down regulated by plasminogen activator inhibitor-
1(PAI-1). A delicate balance between coagulation and anticoagulation is necessary to prevent 
pathophysiological conditions such as excessive bleeding or thrombosis. tPA: tissue plasminogen 
activator; PAI: Plasminogen activator inhibitor; AP: Anti-plasmin; uPA: Urokinase  plasminogen 
activator;TM: Thrombomodulin; Fib: Fibrinogen. 
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The thrombin-activated fibrinolysis inhibitor (TAFI) is also a known regulator of 
fibrinolysis. TAFI is activated by thrombin/thrombomodulin complex (Bajzar et al., 
1996; Wang et al., 2000). Active TAFI removes lysine residues from fibrin, which are 
essential for the binding of tPA, plasminogen, and plasmin. (Dempfle, 2007). The fibrin 
thus loses its co-factor activity leading to less plasmin, and the residual plasmin finds less 
fibrin binding sites, resulting in an increased resistance of the clot towards plasmin 
proteolysis (Dempfle, 2007). 
1.7. Arterial and venous thrombosis 
Arterial and venous thrombosis are distinct diseases with respect to their 
epidemiology and treatment strategies. Arterial thrombus occurs at the sites of arterial 
injury and high shear stress. Whereas, venous thrombi occurs at the sites of undamaged 
vein wall and low shear stress. Arterial thrombus results in white thrombi (platelets rich), 
whereas venous thrombus results in red thrombi (red cells rich). In this context, classical 
arterial thrombosis-associated risk factors such as hypertension have not been shown to 
influence venous thrombosis.  Likewise, venous thrombotic risk factors such as hyper 
activation of FVIII or imbalance in fibrinolysis does not aggravate the risk of arterial 
thrombosis (Lijfering et al., 2011).   
Arterial thrombosis is a formation of thrombus within an artery, which leads to 
myocardial infarction, ischemic stroke, and manifestation of peripheral arterial diseases 
(Albers et al., 2008; Van de Werf et al., 2008). It occurs after the rupturing or slow 
destruction of unstable atherosclerotic plaques in the coronary circulation(Jackson, 
2011). Risk factors for arterial thrombosis include high blood pressure, age, genetic 
factors and smoking. Although coagulation cascade activation is indisputably implicated 
in arterial thrombosis, platelet activation plays a primary role in arterial thrombosis. 
Hence, the use of anti-platelet drugs is the most effective therapy for the arterial 
thrombosis and its complications (Lange and Hillis, 2004).  
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively 
known as venous thromboembolism (VTE). Contrary to arterial thrombosis, venous 
thrombosis and its complication are not usually linked with vascular pathologies. Instead, 
venous thrombosis is associated with the dysregulation of coagulation proteins or venous 
stasis. In 1870, Rudolf Virchow postulated the Virchow’s triad, which has been the base 
for understanding the pathophysiology of venous thrombosis. The triad proposed the 
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 changes in blood flow, vessel wall and blood composition (Fig. 1.5). A major 
complication of venous thrombosis is PE, which occurs when the thrombus breaks away     
Figure 1.6: Virchow’s Triad: Rudolf Virchow’s triad proposing the changes in blood flow, vessel wall 
injury and hypercoagulation, the prime factors causing venous thrombosis. 
and translocates to the minor vasculature areas, especially pulmonary artery (Owens and 
Mackman, 2010). Numerous studies have been reported that show the increased risk of 
VTE with age. Human bleeding disorders and its related genetic deficiencies are fairly 
known, but complete knowledge of genetic factors related to the increased susceptibility 
towards thrombosis remains unclear.  
1.8. Factor VII activating protease (FSAP) 
Factor VII activating protease (FSAP) belongs to a serine protease family and 
circulates in plasma at a concentration of 12 µg/ml (Choi-Miura et al., 1996; Kannemeier 
et al., 2001). The structure of FSAP consists of various structural modules, including 
three-epidermal growth factor (EGF) like domains, a kringle and a serine protease 
domain, which mimics the high structural homology to uPA, plasminogen and 
hepatocyte growth factor (Choi-Miura et al., 1996; Hashimoto et al., 1997). FSAP 
derived its name because of its functional ability to activate factor VII independent of TF 
(Romisch et al., 1999). In addition, due to the binding ability of FSAP to hyaluronic acid, 
it is also called hyaluronan-binding protein 2 (HABP2). As it regulates pro-urokinase 
(pro-uPA) and factor VII activation (VIIa) activation, a role in the regulation of both 
coagulation and ﬁbrinolytic system has been proposed (Romisch et al., 1999). Various 
serine protease inhibitors like, serpins, α1-proteinase inhibitor, α2-plasmin inhibitor, C1-
inhibitor as well as plasminogen activator inhibitor-1 (PAI-1) and protease nexin-1(PN-
1), inhibit activated FSAP rapidly (Choi-Miura et al., 2001). As yet the specific in vivo 
functions of FSAP are unknown (Fig. 1.7). 
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Figure 1.7: Structure of factor VII activating protease (FSAP): FSAP has 560 amino acids representing 
a 23 amino acid signal peptide trailed by three epidermal growth factor domains (EGF 1-3), a kringle 
domain, and a catalytic serine protease domain. The activation through cleavage of the Arg313–Ile314 
located in front of the serine protease domain results in a 50 kDa heavy chain and 25 kDa light chain. Both 
the chains are bound by a disulfide bridge. The enzyme is inactivated through two additional cleavages, 
one located in the EGF-3 domain (between Lys169 and Arg170) and the other located in the serine 
protease domain (Arg480). The heavy chain is cleaved in two fragments of 25 kDa whereas the light chain 
is cleaved into fragments of 18 and 8 kDa. (Kanse et al., 2012). 
1.9. Single nucleotide polymorphisms and FSAP gene 
 There are two single nucleotide polymorphisms (SNP) existing in the FSAP 
encoding gene i.e., G534E (Marburg I) and E393Q (Marburg II) that lead to an exchange 
of a single amino acid in the protease domain leading to the reduction of enzymatic 
activity (Romisch, 2002). About 5% of the Western Europeans are carriers of these SNPs 
(Romisch, 2002). MI-SNP carriers are susceptible to getting late complications of 
atherosclerosis (Gardener et al., 2011), carotid stenosis (Willeit et al., 2003), vascular 
calcification (Zakai et al., 2011), liver fibrosis (Wasmuth et al., 2009) and stroke 
(Trompet et al., 2011). In one study, it was shown that Marburg-I SNP (MI-SNP) results 
in 50-80% decline in the proteolytic activity of FSAP (Sedding et al., 2006). Earlier, 
Romisch and colleagues demonstrated that FSAP-MI had reduced activity towards pro-
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uPA activation in vitro but there was no change in the activation of FVII (Romisch, 
2002). However, FVII activation by FSAP remains a contradictory issue (Stavenuiter et 
al., 2012).  
 In order to further investigate the functional differences between FSAP and 
Marburg-I carriers, another study was carried out where a wire induced arterial stenosis 
was performed in mice. Application of Marburg I variant exhibited significantly higher 
neointima formation compared to wild-type FSAP (Sedding et al., 2006). Several studies 
demonstrated the effects of FSAP outside the coagulation system. Recently a protective 
role of FSAP in liver fibrosis (Borkham-Kamphorst et al., 2013) and the regulation of 
endothelial permeability has been reported (Mambetsariev et al., 2010).  
1.10. FSAP in thrombosis and haemostasis 
 FSAP has high structural homology to plasma haemostasis factors like 
plasminogen, urokinase and hepatocytes growth factor activator (Choi-Miura et al., 1996; 
Hashimoto et al., 1997). This information primarily has driven us to search for its 
functions in coagulation cascade and fibrinolytic pathway (Fig. 1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Dual function of FSAP in vitro: FSAP acts as a procoagulant due to its role in factor VII 
activation and inhibition of TFPI.It also exihibits its profibrinolytic properties via pro-uPA activation. 
TFPI: Tissue factor pathway inhibitors; Pro-uPA: Pro-urokinase plasminogen activator; FDP: Fibrin 
degradation products. 
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Initial studies identified FSAP to be responsible for factor VII and pro-uPA activation 
(Romisch et al., 1999). However, prothrombin time (PT; extrinsic pathway) and plasma 
recalcification time were reduced with the addition of exogenous FSAP and there was no 
influence on partial thromboplastin time (pTT; intrinsic pathway). This confirms that 
FSAP functions majorly through the extrinsic pathway and not by the intrinsic pathway 
(Romisch, 2002). FSAP Marburg-I variant represents a general cardiovascular risk factor 
and might also be involved in venous thromboembolism (Hoppe et al., 2005; Ireland et 
al., 2004). However, others could not reproduce these findings (Franchi et al., 2006; 
Gulesserian et al., 2006; van Minkelen et al., 2005). It was later proposed by Kanse et al., 
that FSAP inhibits TFPI in vitro (Kanse et al., 2012). Thus, these studies were unclear 
with respect to the pathophysiological significance of FSAP in thrombosis and 
haemostasis. Sidelmann and colleagues observed elevated levels of ciruclating FSAP in 
deep vein thrombosis patients (Sidelmann et al., 2008). Recently, deep vein thrombosis is 
also associated with an elevation in the ciruclating FSAP (Sidelmann et al., 2008). MI-
SNP was also found to be strongly associated to the  late complications of carotid 
stenosis indicating that FSAP is involved in the development of atherosclerosis (Willeit 
et al., 2003) and stroke (Trompet et al., 2011). 
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2. AIM OF THE STUDY 
Due to the association of Marburg-1(MI) SNP with venous thrombosis and other 
vascular diseases, we intended to define its function in thrombosis and haemostasis in 
vivo. The major aim of this study was to characterize FSAP deficient (knockout) mice 
using well-established mouse models for thrombosis and haemostasis. 
The main questions addressed in this thesis are as follows: 
1. Does endogenous FSAP play a role in haemostasis?  
2. What is the role of endogenous FSAP in thrombosis? 
3. Does FSAP activate factor VII in vivo? 
4. Does FSAP inactivate TFPI in vivo? 
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3. Materials and Methods 
3.1. Animal study: FSAP-/- mice 
FSAP-/-(Knockout) mice were generated as described previously (Borkham-
Kamphorst et al., 2013). These mice were then backcrossed with C57BL/6J mice for 10 
generations (F10) and heterozygous crosses were set up to generate FSAP-/- mice and 
littermate controls. Age and gender matched animals were used in all the experiments.  
Animals underwent an acclimatization period of one week before the experimental 
procedures. The animals were maintained in the same room under specific pathogen free 
(SPF) conditions. All interventions were performed in full compliance with the 
institutional and German protection laws and approved by the local animal welfare 
committee. (V54-19c 20-15 (1) GI 20/2 Nr. 90/2010 andV54-19c 20-15 (1) GI 18/11 
Nr.60/2008).  
3.2.Tail-bleeding assay  
 Mice (5-6 weeks) were matched for sex and weight and anesthetized with 100 
mg/kg Ketamine and 10 mg/kg Xylazine cocktail. After the complete anesthesia, mice 
were placed on the heating pad (37°C).  The tails were then amputed (approximately 4-5 
mm length) using a sharp scalpel and immediately immersed (approx. 2 cm) into a 15 ml 
tube contained pre-warmed buffer (isotonic normal saline) at 37°C (Fig. 3.1). This buffer 
was constantly changed every minute, till 12 minutes. 
 
Figure 3.1: Murine model of haemostasis: Tail bleeding times of WT and FSAP-/- mice (n=10) were 
monitored by positioning the resected (5 mm) tail in a tube containing saline at 37°C which was changed 
every minute. The experimental set up was for 12 min after which the hemoglobin content was measured 
spectrophotometrically. (A) Animals placed on the warm plate at 37°C (B) Amputation of the tail tip (C) 
Amputed tail tip immersed immediately in to the normal saline tubes  (D) Visualization of bleeding pattern. 
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To measure hemoglobin content, samples were centrifuged at 600g for 5 minutes at 20°C 
and resuspended in 3 mL of red blood cell (RBC) lysis buffer (8.3M NH4Cl, 1M KHCO3, 
3.7 mM EDTA, pH 7.3). After a standing period of 5 minutes at room temperature, the 
tubes were again centrifuged at 600g, for 5 minutes at 20°C. The supernatant was 
collected and the hemoglobin content was determined spectrophotometrically at 560 nm. 
The primary (initial arrest) and re-bleeding (initial arrest and re-bleeding) times were 
established from the experimental data.  
3.3. Ferric chloride (FeCl3) induced venous thrombosis 
 The FeCl3 induced inferior vena cava (IVC) thrombosis model was used as 
previously described (Wang et al., 2006). A midline laparotomy was performed on 
anesthetized mice (10-12 weeks). The intestines were exteriorized and covered with  
 
Figure 3.2: FeCl3 induced venous thrombosis: Venous thrombosis was induced by topical application of 
a filter paper soaked with 3.5% FeCl3 on the IVC for 3 min. Thrombus protein content was measured after 
30 min. 
gauze soaked in physiologic saline to prevent desiccation. A section of IVC, between the 
renal and left common iliac veins was cleared and separated from the aorta by dissection 
and a piece of Whatmann filter paper (1.0 × 1.0 mm) pre-saturated in a solution of 3.5% 
FeCl3 in 1% phosphate buffer saline (PBS) was placed on the surface of the IVC for 3 
minutes. After 30 minutes of the initial application of filter paper, the entire section of 
IVC (5-6 mm) was removed for downstream processing (Fig. 3.2). Excessive moisture 
was removed before weighing the thrombus. Thrombi were placed in 200 µL of Tris 
buffer (pH 7.5) supplemented with 20 µL Proteinase K (Fermentas) for overnight 
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digestion at 50°C for 8-10 h, and total thrombus protein content was measured at an 
optical density of 280 nm. In this model the effects of administration of the anti-
coagulant, heparin was also determined. 0.9% saline vehicle or heparin (0.1 IU/g, i.v.) 
was applied 15 minutes before the FeCl3 application. Blood samples were collected in the 
citrated (3.8 % sodium citrate) tubes and processed for plasma separation. 
3.4. FeCl3 induced carotid artery thrombosis 
  Mice (10-15 weeks) were anesthetized and the experiment was performed as 
described by Pozgajova et al. with slight modifications (Moller and Tranholm, 2010; 
Pozgajova et al., 2006). Midline cervical incision was performed to expose the right 
common carotid artery of anesthetized mice and the normal carotid blood flow was 
measured for 5 min using Ultrasound Doppler transonic flow probe (Transonic systems, 
USA). Vascular injury was made with 10% FeCl3 (0.62M on 0.5 × 0.5mm filter paper) 
for 3 min, washed with warm saline and the blood flow was measured for 45 min. This 
blood flow (mL/min) was recorded using Transonic T420 model 0.5 VB probe with a 
chart recorder (Servogor 220, BBC Goerz, Austria). In both models, the time to occlusion 
(TTO) was defined as the time between FeCl3 application on the indicated vessel and the 
lags in flow for 2 min. Embolization was defined as a rapid increase in blood flow (at 
least 0.2 mL/min in 5 min) after stable occlusion occurred. Blood was drawn, either 10 
min after stable occlusion or after 45 min without stable occlusion from the IVC into 
3.8% sodium citrate buffer and processed to platelet poor plasma (PPP) by centrifugation 
(5000g for 10 min). The normal and thrombotic carotid arteries were frozen at -80°C for 
further downstream processes (Fig. 3.3).  
3.5. Application of exogenous FSAP 
In order to achieve the normal circulating FSAP levels, a blood volume of 2mL 
was assumed in a 25g mouse and 1.2mg/kg body weight of human plasma FSAP was 
applied. The control group was administered with FSAP carrier buffer (high-end (HE) 
buffer; 5 mM Citrate pH 4.5, 0.2 M Arginine and 0.2 M Lysine). FSAP/HE buffer 
administration done was via the lateral tail vein. The injection volume was 100 µL and 
this was done 15 min before the induction of carotid thrombosis. Blood was then drawn, 
either 10 min after stable occlusion or 45 min without stable occlusion from the IVC into 
3.8% sodium citrate and processed to platelet poor plasma (PPP) by centrifugation at 
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5000g for 10min. The normal and thrombotic carotid arteries were then frozen at -80°C 
for further downstream processes (Fig. 3.3). 
 
Figure 3.3: Carotid artery thrombosis: (A) After anesthesia the mice was placed in a supine position. 
(B)Mandible to suprasternal notch area was cleaned by disinfectant. (C)A midline incision extended from 
mandible to suprasternal notch was made to expose the anterior cervical triangle which was then blunt 
dissected to free the right carotid artery from the surrounding tissue. (D) Free right carotid artery was 
separated by surgical suture. (E)Normal blood flow was measured using flow probe (Transonic T420 model 
0.5 VB). (F)Transparent flexible spacer was placed below the right carotid artery to avoid the dilution of 
FeCl3. (G).Whatmann filter paper (1.5 x 1.5 mm) saturated with 10% FeCl3 was placed over the adventia of 
the right carotid artery for 3 min.(H&I)Blood flow measured using flow probe after FeCl3 exposure. (J) 
Indicated the complete occlusion of carotid artery and arrows indicates visible aggregated platelets). (K) 
Normal and thrombotic carotid arteries (Right carotid artery- R; Left carotid artery - L). (L) Chart recorder 
connected with the transonic flow meter.  
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3.6. FeCl3 induced mesenteric arteriole thrombosis 
 Mice (5-6weeks) were anesthetized and the experiment was performed as 
described by Pozgajova et al. with slight modifications (Pozgajova et al., 2006). In brief, 
2µg 488-Dylight–coupled GPIX-IgG derivative (X488; Emfret Analytics) in 150 µL PBS 
was injected retro-orbitally and the mesentery was gently exteriorized using a midline 
abdominal incision approach. Arterioles (35 to 60µm diameter) were visualized with a 
Zeiss Axiovert 200 inverted microscope (10X) equipped with a 100-W HBO fluorescent  
 
Figure 3.4: FeCl3 Induced thrombosis in the mesentery: Vascular injury created in mesenteric arterioles 
by topic application of 20% FeCl3  (A &B). Before initiating the vascular injury, mesenteric arterioles were 
exteriorized and spread on the transparent Petridish as displayed (C). Live images and videos were captured 
with a Zeiss Axiovert 200 inverted microscope (Carl Zeiss, Jena, Germany) with a 63 X/0.75 Ph1 objective, 
a 100-W HBO fluorescent lamp source, and a CCD camera (CV-M300; Visitron Systems, (puchheim, 
Germany) connected to an AG-7355 S-VHS video recorder (Panasonic, Matsushita Electric, Osaka, Japan). 
Video taped images were analyzed using a computer assisted image analysis program, Meta View Version 
5.0 (Visitron Systems). 
lamp source and a CCD camera (CV-M300) connected to an S-VHS video recorder (AG-
7355; Panasonic, Matsushita Electric, Tokyo, Japan). A drop of FeCl3 solution (20%) was 
used to create vascular injury in the arterioles. Arterioles were monitored for 40 min or 
until complete occlusion (blood flow stoppage for more than 1 min). Firm platelet 
adhesion was determined by the number of fluorescently labeled platelets that deposited 
on the vessel wall, 5 min after injury. A thrombus was defined as a platelet aggregate 
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larger than 10µm in diameter. Thrombus stability was characterized as the number of 
embolus events (thrombi larger than 10 µm in diameter) that detached during the 
observation period from the viewing field (Fig. 3.4). These experiments were performed 
in collaboration with Prof. Bernd Nieswandt (Universität Wurzburg, Germany).  
3.7. Collagen/ epinephrine model of venous thromboembolism 
Mice (10-12 weeks) were anesthetized and maintained on pre-warmed heating pad 
(37°C). Collagen (0.8 mg/kg, Horn collagen, Nycomed, Germany) and epinephrine (60 
µg/kg, Jenaphrama, Germany) cocktail was injected through jugular vein (Pozgajova et 
al., 2006). Breathing time was monitored and the time taken for the complete respiratory 
arrest was recorded. Blood was collected immediately in citrate buffer and processed for 
obtaining plasma. Mice were then perfused with cold PBS (1%). Lungs were retrieved 
and immediately processed for optimum cutting temperature (OCT) followed by freeze 
storage at -80°C. H&E staining was performed and the thrombus load was assessed.  
3.8. FSAP activity assay 
 Total FSAP activity was measured by an immunocapture activity with slight 
modifications (Kanse et al., 2012b). 96 well plate was coated with 10mg/mL anti-FSAP 
rabbit polyclonal antibody (2µg/mL) in coating buffer (15 mM Na2CO3, 35 mM 
NaHCO3, pH 9.6) over night at 4°C, followed by blocking with standard buffer (20 mM 
Na-citrate, 150 mM NaCl, 100mM Arginin, pH 6.0) containing 3% BSA. Standard 
plasma and mouse plasma were diluted (1:200) in a standard buffer containing 0.1% 
Tween 80, 1% BSA and 100U/mL unfractionated heparin (Ratiopharm, Germany) and 
applied on the plate, incubated for 1 h at room temperature (RT) and washed three times 
in TBS with 0.1% Tween 20. Recombinant single-chain pro-uPA (1 µg/mL; Saruplase, 
Grünenthal, Stolberg, Germany in TBS with 0.1% Tween 80, 2 mM CaCl2, pH 7.2) was 
added and incubated for 5 min followed by chromogenic substrate S-2444 (2.5mM) L-
pyroglutamyl-glycyl-L-arginine-p-nitroanilinedihydro-chloride;HaemochromDiagnostica, 
Essen, Germany) and further incubation at 37°C. Absorbance was recorded at 405 nm, 
every min with micro plate reader EL808 (Biotek Instruments, Winooski, OR, USA) for 
60 min (37°C). For the assay, calibration curves were established through a dilution series 
of Standard Human Plasma (SHP, Siemens Diagnostics, Marburg, Germany). SHP served 
as reference for the measured FSAP activity, which was defined as 1 plasma equivalent 
unit (1000 mU/mL). 
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3.9. Fibrin plate assay 
A solution containing fibrinogen (9.5 µM) from human plasma (Sigma) was laid 
over dishes and clotted by the addition of human thrombin 15 IU (Enzyme Research 
Laboratory). Fresh plates were prepared and incubated at room temperature for 30 min 
before the experiment. 10 µL of uPA (3ng) and FSAP (10 nM, 30 nM, 60 nM and 90 nM) 
alone or together with uPA and plasma euglobulins of normal and experimental plasma 
(10 µL) were pipetted onto the surface of the fibrin plate (n=3), and incubated further at 
room temperature overnight. Plasma euglobulin preparation: Plasma (150 µL) was 
acidified (1:10 dilution) with 1% acetic acid (pH 5.9) on ice. After 15-20 min on ice, the 
precipitate was centrifuged (800g for 5 min at 0°C) and dissolved in 150µL of tris buffer 
(pH 7.5). The lytic areas were determined as a measurement of fibrinolytic activity. To 
determine the pro-uPA activation of pure human FSAP, 0.5% of agarose solution (5 mL) 
was used additionally to create solid matrix well and to measure the exact pro-uPA 
activity.  
3.10. Flow cytometry and hematological parameters 
Heparinized whole blood was diluted 1:20 with modified Tyrode-HEPES buffer 
(134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES [N-
2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid], pH 7.0) containing 5 mM glucose, 
0.35% bovine serum albumin (BSA), and 1 mM CaCl2. For glycoprotein expression and 
platelet count, blood samples were incubated with appropriate fluorophore-conjugated 
monoclonal antibodies for 15 min at room temperature and were directly analyzed on a 
FACS calibur (Becton Dickinson, Heidelberg, Germany).Whole blood, drawn from the 
inferior vena cava of anesthetized mice into a one-tenth volume of 0.1 M citrate, was used 
for complete blood cell analysis.  
3.11. In situ casein zymography  
The assay was performed essentially as described in the standard protocol 
(BODIPY FL E6638, Green Fluorescence). Cryostat sections (5 µm in thickness) of 
unfixed thrombotic carotid artery tissue were air-dried for 2 min. Mastermix was prepared 
and 30 µL was dropped on each section and covered with small cover slip. The slides 
were then incubated immediately at 37°C for 4 h and pictures were taken using a 
fluorescent microscope (Leica). Preparation of master mix for 15 sections: 1% agarose 
(500µL) was prepared under sterile conditions and prewarmed at 37°C. To this 10µg/mL 
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plasminogen (2.6 µL), 100 µg/mL DAPI (0.5 µL), casein E6638 (50 µL) was added. 30 
µL of the same mixture was then poured on each of the sections. For negative control, 
prior to the master mix, sections were pre-incubated for 30 min with 0.5 mM amiloride 
(uPA inhibitor). This assay demonstrated the total substrate turnover at specified time 
point.  
3.12. Casein zymography 
Casein zymography is used to measure the plasminogen activators (uPA and tPA). 
Mice plasma samples (0.5µL) were loaded under a non-reduced and non-boiled condition 
onto a 10% SDS polyacrylamide gel. The gel was washed at 25°C for 30 min with 2.5% 
Triton X-100 to remove SDS and overlayed on the polymerized agarose matrix plate 
followed by incubation at 37°C. Agarose matrix plate preparation: Mix 1% agarose 
solution (3 mL) with 8% milk solution (1.5 mL), 1 M PBS (4.5 mL), 10% sodium azide 
(100µL) and plasminogen (40 mg/mL)at 37°C on a pre-warmed station, spread the whole 
solution (9 mL) quickly on the GelBond film (85 x 100 mm, thickness 0.2 mm, Germany) 
and allow it to polymerize for 30 min. Activity of plasminogen activators, were measured 
by the zone of clearance, according to their molecular weight.  
3.13. Measurement of circulating factors and blood parameters  
Whole blood, collected from the inferior vena cava of anesthetized mice in 0.1 M 
citrate (one tenth volume), was used to prepare plasma. Circulating coagulation factor 
activities in citrated mouse plasma were measured as prothrombin time-PT (FII, FV, 
FVII, FVIIa, FX) or activated partial thromboplastin time-aPTT (FVIII, FIX, FXI, FXII) 
in single factor-depleted human plasma relative to that of human standard plasma 
(Siemens Healthcare, Marburg, Germany). Briefly, mouse plasma samples were pre-
diluted to three different concentrations in imidazole buffer (50 mM imidazole, 150 mM 
NaCl, 1% BSA, pH 7.4) to obtain clotting times within the range of the human reference 
plasma. The prothrombin time was measured at a final 1:6600 dilution of the tissue 
factor/phospholipid reagent (Thromborel S, Siemens Healthcare) to achieve reasonably 
long clotting times (human control plasma: about 140-180 s). The aPTT reagent was used 
without pre-dilution. The clotting was measured in a micro plate reader with increase in 
turbidity at 405 nm.  
 PT assay: 40 µL imidazole buffer was mixed with 60 µl of diluted plasma sample, 
20 µL depleted plasma, 30 µL Thromborel S (1:1000 dilution in imidazole buffer), and 
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incubated for 8 min at 37°C. 50 µL 20 mM CaCl2 was added to start the clotting reaction. 
FVIIa was quantified in the PT assay using a soluble recombinant tissue 
factor/phospholipid mix as described recently(Etscheid et al., 2012b). 
 aPTT assay: 30 µL imidazole buffer was mixed with 10 µL of the diluted mouse 
plasma or human reference plasma, 30 µL single factor-depleted plasma and 30 µL of a 
PTT reagent (Actin FS; Siemens Healthcare). The incubation condition, clotting start and 
measurement were as described previously for the PT.   
 TFPI Assay: TFPI activity in mouse plasma was quantified as described 
recently(Kanse et al., 2012a) using the Actichrome TFPI activity assay (American 
Diagnostica; Pfungstadt, Germany). This assay measures in TFPI-depleted human 
plasma, the ability of mouse plasma TFPI to inhibit the activation of FX by the TF/FVIIa 
complex. Human TFPI reference standard in TFPI-depleted human plasma served as 
calibration curve. To test if mouse FSAP can inactivate mouse TFPI we used a polyclonal 
antibody to capture FSAP from mouse plasma. Thereafter, mouse recombinant TFPI 
(R&D Systems, Wiesbaden, Germany) was incubated in the wells for 60 min at RT and 
TFPI activity was measured as described above. Dr. Michael Etscheid made all these 
measurements from the Paul Ehrlich Institute, Langen, Germany.  
3.14. Histology and immunohistochemistry 
Harvested tissues were immediately embedded in OCT compound (Tissue-Tek, 
Miles Inc), snap-frozen in pre-cooled 2-methyl butane, and stored at -80°C until further 
analysis. 5 µm cross sections were made through the whole frozen tissue and stained with 
Hematoxylin and Eosin (Adler lab: http://www.jhu.edu/adlerlab/protocols/histo_HE) and 
Carstairs stain (online reference protocol from Electron Microscopy Sciences 
(EMS):http://www.emsdiasum.com/microscopy/technical/datasheet/26381.aspx). Carotid 
artery thrombosis vessels were stained with TFPI (H-120, 200 µg/mL, 1:100; Santa Cruz 
Biotech),vWF (Rabbit polyclonal, 400µg/mL; 1:500, DAKO, Denmark), fibrinogen 
(Rabbit polyclonal, 400µg/mL; 1:500, DAKO, Denmark), Fibronectin (Rabbit polyclonal, 
1mg/mL; 1:400, Abcam). Light microscopy and fluorescence microscope images were 
captured using Leica Microsystems, Wetzlar, Germany equipped with a High speed 
VISitron systems camera using MetaMorph imaging software version series 7.0.  
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3.15. SDS-PAGE and western blotting 
Plasma or tissue extracts were separated by 10 or 12% SDS-PADE under non-
reducing conditions. Proteins were transferred onto polyvinylidene difluoride (PVDF) 
membrane (Millipore, Billerica, MA, USA) and probed with primary antibodies. Bound 
antibodies were detected using horseradish peroxidase conjugated secondary antibodies 
(Swine anti rabbit polyclonal; P0217, DAKO, Denmark) and the enhanced 
chemiluminescence detection system (Amersham-Pharmacia, GE Healthcare, Germany). 
Blots were re-probed for either the plasma protein ceruloplasmin or actin as appropriate. 
Primary antibodies used: TFPI (Rabbit polyclonal; sc-28861, Santa Cruz Biotech, 
Germany), plasminogen (Rabbit polyclonal; A0081, DAKO, Denmark), ceruloplasmin 
(Rabbit polyclonal; A0031, DAKO, Denmark) and FSAP (Rabbit Anti-mouse; ME New). 
3.16. Measurement of active TFPI by ligand blotting with Biotinylated FXa 
Factor X (Xa, 2 U/µL, Invitrogen) was dialysed against 100 mM sodium 
phosphate buffer (pH 7.4). A 20 mg/mL Sulfo-NHS-LC-Biotin (ThermoFisher scientific, 
Germany) stock solution in DMSO (stock solution) was added to the protein solution to 
obtain a 10-fold molar excess of biotinylation reagent over protein. The biotinylation 
reaction was allowed to proceed for 60 min and the unbound biotin was removed through 
dialysis. This biotinylated factor Xa was used as a primary probe for the ligand blot to 
detect the active TFPI on PVDF membranes. 
3.17. Statistical Analysis  
Results were shown as mean ± SD. Statistical analysis between WT and FSAP-/- 
mice was assessed by nonparametric Mann-Whitney U test. Differences in time course of 
processes was analysed using Kaplan Meier plots with log-rank (Mantel-Cox) test 
comparisons. More than 2 groups are analyzed by one-way ANOVA followed by 
Bonferroni posthoc test.  *P<0.05, **P<0.01, ***P<0.001 and n.s. indicates not 
significant. Western blots were quantified using Image J, NIH software, (version 1.62).  
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4. RESULTS 
4.1. Breeding and genotyping of FSAP-/- (knockout) mice   
 We have previously reported the generation of FSAP-/- mice (Borkham-Kamphorst 
et al., 2013). FSAP+/- mice from each generation were crossed with clear C57BL/6J mice 
for at least 10 generations (F10). FSAP-/- mice showed no difference in the normal 
breeding parameters like gestation period, litter size, weaning period etc. Cage activity, 
food intake, water intake, nature of the feces, etc., were identical. There were no 
differences in fertility, development and survival rate between FSAP-/- mice and WT 
littermates. FSAP genotypes were confirmed by PCR using genomic DNA extracted from 
ear punch samples (NucleoSpin® Tissue kit, Macherey-Nagel, Germany) with 
oligonucleotides 5´- GAA TTC ATG GAG GCT TTG -3´ for both targeted neomycin 
gene and endogenous gene in combination with 5´-CCG TGT CCT GCT GCT AAT-3´ 
for endogenous gene or 5´-GCA GCG CAT CGC CTT CTA TC-3´ targeted neomycin 
gene.  
4.2. Phenotypic difference between WT and FSAP-/- mice 
FSAP-/- mice displayed no spontaneous bleeding events and blood pressure and 
heart rates were normal. Gross and microscopic histological evaluation revealed no 
notable differences in the FSAP-/- mice when compared to WT mice. Deletion of 
FSAP had no significant impact on peripheral platelet counts and basic blood cell  
Table 4.1: Basic blood parameters in WT and FSAP-/- mice 
BLOOD CELLS WT FSAP-/- mice 
Platelets (x 103/µL) 988.75 ± 194.75 971.25 ± 104.04n.s 
MPV (fL) 5.36 ± 0.15 5.24 ± 0.11n.s 
RBC (x 106/ µL) 9.56 ± 2.12 9.81 ± 1.61n.s 
WBC (x 103/µL) 14.56 ± 2.59 13.30 ± 3.60n.s 
HCT (%) 52.22 ± 11.91 52.64 ± 9.00n.s 
 
 Basic blood parameters were assessed using diluted whole blood with sysmex hematology analyzer in WT 
and FSAP-/- mice. Results were expressed as mean ± SD (n=6). *p<0.05. n.s. indicates not significant. HCT, 
hematocrit; RBC, Red blood cells; WBC, White blood cells; MPV, Mean platelet volume. Experiment 
performed with the help of Ina Thielman and Martina Morowski at University of Wurzburg, Germany. fl: 
Femtolitre; µL: microliter.  
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counts of RBCs and WBCs (Table 4.1).  Also, there were no significant differences in 
the expression of the prominent platelet surface receptors including integrins, GPVI, 
GPV, etc., (Table.4.2). 
 
Table 4.2: Levels of platelet glycoproteins in wild type and FSAP-/- mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of glycoproteins on the platelet surface was determined by flow cytometry. Diluted whole blood 
was incubated with FITC-labeled antibodies at saturating concentrations for 15 min at RT and platelets 
were analyzed directly. Results were expressed as mean fluorescence intensity (MFI) ± SD (n=6). *P<0.05 
and n.s. indicates not significant. α2, integrin α2; β1, integrin β1; αIIbβ3, integrin αIIbβ3. Experiment 
performed with the help of Ina Thielman and Martina Morowski at University of Wurzburg, Germany. 
4.3. FSAP is essential for normal primary haemostasis 
In a tail-bleeding model  (Fig. 4.1) a significant haemostatic defect was observed in 
FSAP-/- mice. FSAP-/- mice exhibited prolonged initial bleeding compared to 
littermate WT mice in a tail-bleeding test (≈ 400s and 200s respectively), although the 
differences were not significant (Fig. 4.1A). Within the 15 min time scale of the 
experiment, about 50% FSAP-/- mice (≈ 600s) displayed re-bleeding compared to 10% 
of the WT littermates (≈300s) (Fig. 4.1B). The total blood loss was measured 
EXPRESSION (MFI) WT FSAP-/- 
GPIb 331.00 ± 16.73 337.50 ± 7.58n.s 
GPV 297.33 ± 12.48 286.83 ± 3.60n.s 
GPIX 414.67 ± 6.92 419.00 ± 2.53n.s 
GPVI 16.33 ± 0.52 16.17 ± 0.75n.s 
CLEC-2 146.50 ± 5.75 140.33 ± 5.75n.s 
α2 47.83 ± 1.72 48.33 ± 1.03n.s 
α5 21.67 ± 1.75 21.20 ± 0.45n.s 
β1 121.50 ± 3.45 118.67 ± 3.61n.s 
β3 216.83 ± 7.39 208.33 ± 7.55n.s 
αIIbβ3 524.33 ± 10.33 519.83 ± 12.21n.s 
CD9 955.00 ± 25.04 982.33 ± 18.28n.s 
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spectrophotometrically and it showed significantly higher blood loss (Fig. 4.1C) in 
FSAP-/- mice due to the frequent re-bleeding events. These results led us to further 
investigate the progression of thrombosis in FSAP-/-mice. 
 
   
Figure 4.1: Haemostasis and thrombosis in FSAP-/- mice. Tail bleeding time of WT and FSAP-/- mice  
(n=10) were monitored by positioning the resected tail in a tube containing saline at 37°C and these tubes 
were changed in every min. The experiment was stopped after 12 min and hemoglobin content was 
measured spectrophotometrically. (A) primary bleeding and (B) re-bleeding was recorded for each mouse 
during the course of the experiment and plotted as in percentage blocks. (C) Total blood loss over the 12 
min period was recorded for each mouse and expressed in percentage blocks. Data were analyzed by 
Welch’s t-test. *P<0.05, **P<0.01 and n.s. indicates not significant. 
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4.4. Reduced thrombus stability in FSAP-/- mice 
4.4.1. FeCl3 induced venous thrombosis: Reduced thrombus volume in FSAP-/- mice  
 Venous thrombosis was induced in the inferior vena cava (IVC) using 3.5% FeCl3 
The thrombus protein content as well as thrombus weight was higher in WT mice 
compared to FSAP-/- mice (Fig. 4.2A and B), although these differences were not 
statistically significant. Thrombus formations in both strains was reduced by 
 
Figure 4.2: FeCl3 induced venous thrombosis in WT and FSAP-/- mice: Venous thrombosis was induced 
using a topically applied filter paper soaked with 3.5% FeCl3 to the IVC for 3 min. Thrombus protein 
content (A) and thrombus weight (B) were measured after 30 min. Data were expressed in scatter plot with 
mean bar. *P<0.05 and n.s. indicates not significant.	  
heparin application (100 U/kg, intravenously), consistent with the fact that this model 
relies strongly on the plasmatic coagulation factors (Fig. 4.2A and B).  
 
4.4.2. Collagen /epinephrine induced pulmonary thromboembolism  
 To investigate the consequences of FSAP deficiency in vivo, we examined WT 
littermates and FSAP-/- mice in a model of lethal pulmonary thromboembolism induced by 
infusion of collagen and epinephrine through jugular vein. Mice of both genotypes died 
within 4 to 8 min except that the onset of death was significantly later in the FSAP-/- mice 
(Fig. 4.3A). The deposits of platelet/fibrin complexes were examined through histological 
section of lung tissue through H&E staining and it showed reduced platelet/fibrin complex 
in FSAP-/- mice compared to WT mice (Fig. 4.3B). Although there were no differences in 
number of minor occluded vessels in both the genotypes, the major vessels were 
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obstructed in WT mice. Thus, lack of endogenous FSAP, playing a protective role in 
models of venous thrombosis and pulmonary thromboembolism.   
 
Figure 4.3: Pulmonary thromboembolism: (A) Kaplan Meier plot of mortality associated with the 
injection of collagen (0.8 mg/ Kg body weight.) and epinephrine (60 µg/Kg body weight) via jugular vein in 
WT (n=10) and FSAP-/- (n=10) mice. (B) Cross section (5 µm) of a collagen epinephrine induced 
pulmonary embolism model lung tissue stained with hematoxylin and eosin from WT (n=3) and FSAP-/- 
(n=3) mice.  Arrow indicates the micro vascular thrombosis. Data were analyzed with Kaplan Meier plot 
and expressed as % survival rate. *P < 0.05, **P < 0.01 and n.s. indicates not significant. 
 
 
4.4.3. FeCl3 induced carotid artery thrombosis 
Thrombus formation was also induced in the carotid artery by 10% FeCl3 application and 
occlusion was determined by measuring blood flow using a Doppler flow probe (Fig. 
4.4B). Blood flow decreased progressively and led to occlusion of the artery in 95% of 
the animals of the WT genotype. Mean initial flow rates ranged from 0.6 to 1.2 mL/min 
in WT and FSAP-/- mice. In FSAP-/- mice, thrombus formation was considerably delayed 
(P< 0.05) and thrombus was stable only in 56% of the mice (Fig. 4.4A). Cross sections of 
thrombi from WT and FSAP-/- mice were stained with H&E as well as Carstairs staining 
to visualize matrix (fibrin, collagen, platelets and smooth muscle cells) and thrombotic 
tissue. WT mice had even platelet aggregation whereas FSAP-/- mice had disturbed 
aggregation with a loose structure (Fig. 4.4C and D).  Immunohistochemistry analysis of 
carotid artery thrombosis was also performed to investigate the role of procoagulant 
mediators. In the entire thrombus vWF, fibrinogen and PDGF-BB showed no changes. 
However, changes were observed in FSAP-/- mice with respect TFPI (described under 
section 4.6). 
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Figure 4.4. FeCl3 induced arterial thrombosis in FSAP-/- mice: Vascular injury was induced in carotid 
artery by topic application of 10% FeCl3. (A) The scatter plot shows time to occlusion (TTO) for carotid 
arteries in WT (n=20) and FSAP-/- (n=16) mice. TTO was calculated based on time taken for flow to stop 
completely after vascular injury. Data were represented as percentage blocks. (B) Blood flow in WT and 
FSAP-/- mice during the course of the experiment (n=3). After the carotid artery exposure, normal carotid 
blood flow was measured (Phase 1) then mice were subjected to carotid artery injury with 10 % FeCl3 
solution saturated paper for 3 min (Phase 2). After exposure, vessels were cleaned with normal saline and 
the flow probe was placed around the carotid artery, above the injury site. These processes take 
approximately 2 min, which is shown in the graph as gray scale. Time taken to occlusion (TTO) was 
measured after the vascular injury (Phase 3). If no occlusion was observed till 45 min, then this was 
designated as not occluded and the experiment was stopped manually (Phase 4). Carotid artery 
thrombosis: Representative cross section (5 µm) of carotid artery thrombi (n=5) from WT and FSAP-/- 
mice after hematoxylin and eosin (H&E) staining (C) as well as Carstairs staining representative images 
(D) which represents fibrin (bright red), collagen (bright blue) and platelets (navy blue). WT: Wild-type 
mice; FSAP-/-: FSAP knockout mice. Data were analyzed by nonparametric Mann-Whitney U test. *p < 
0.05 and n.s. indicates not significant. 
 
4.4.4. Vascular injury in mesenteric arterioles: Intravital study 
 FeCl3 induced oxidative vascular injury in mesenteric arterioles model was used to 
test the robustness of these findings. Occlusive thrombus formation was induced in 
mesenteric arterioles by FeCl3 application and assessed by intravital fluorescence 
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Figure 4.5: FeCl3 induced thrombosis in the mesentery: Vascular injury was induced in mesenteric 
arterioles by topic application of FeCl3. (A) Initial thrombus formation was measured (>10 µm) between 
WT and FSAP-/- mice. Data were expressed as scatter plot in percentage blocks. Each dot represents 
individual animals. The scatter plot (B) shows time taken for the occlusion (TTO) of mesenteric arterioles 
in WT (n=15) and FSAP-/- (n=15) mice. Data were expressed in percentage blocks. (C) Embolic events 
(EE) were classified according to the frequency of the events. More than 10 embolic events were 
considered to be a high incidence (EE > 10) and less than 10 embolic events were considered to be low 
incidence (EE < 10) in WT (n=15) and FSAP-/- (n=15) mice. (D) Representative phase contrast images were 
shown for the better illustration. Indicated time points represent min after FeCl3 induced injury. Images 
were captured with a Zeiss Axiovert 200 inverted microscope (Carl Zeiss, Jena, Germany) with a 63 X/0.75 
Ph1 objective, a 100-W HBO fluorescent lamp source, and a CCD camera (CV-M300; Visitron Systems, 
(Germany) connected to an AG-7355 S-VHS video recorder (Panasonic, Matsushita Electric, Osaka, 
Japan). Video tapped images were analyzed using a computer assisted image analysis program, Meta View 
Version 5.0. (Experiment performed with the help of Ina Thielman at University of Wurzburg, Germany). 
Data were analyzed by nonparametric Mann-Whitney U test. *p < 0.05 and n.s. indicates not significant. 
WT: Wild-type mice; FSAP-/-: FSAP knockout mice. 
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microscopy of labeled platelets (Dylight–coupled GPIX-IgG derivative). Adhesion of 
labeled platelets at the site of vascular injury was normal demonstrating that platelet 
response intact in the absence of endogenous FSAP (Fig. 4.5). Time to initial thrombus 
(TIT) formation was indistinguishable in both strains of mice (Fig. 4.5A), where both WT 
littermates and FSAP-/- mice showed approximately 8 to 12 min. Time to occlusion 
(TTO) or stable thrombus formation in FSAP-/- mice was delayed and in 27% of the cases 
the thrombi was not stable and there was no occlusion of the arterioles when compared to 
7% of WT mice (Fig. 4.5B). Thrombi were unstable, loose and detached from the vessel 
wall and the number of embolic events (EE) was higher in FSAP-/- mice compared to WT 
littermates (Fig. 4.5C). Representative intravital microscopy photomicrographs of 
thrombi from WT and FSAP-/- mice are as shown (Fig. 4.5D). Some of the FSAP-/- mice 
occluded like WT littermates, but the intensity of the thrombi was less in FSAP-/- mice 
(Fig. 4.5D). Thus, the facts from different mouse models demonstrate that endogenous 
FSAP is required for the stabilization of clots in vivo. 
4.5. FSAP activity assay  
 A direct chromogenic substrate immuno-capture activity assay for FSAP was used 
to measure the circulatory FSAP concentration through its ability to activate pro-uPA. In 
all the above-described three mouse model experiments, plasma samples were collected 
 
 
Figure 4.6: FSAP activity assay: FSAP activity was measured in plasma samples from all the experiments 
performed in this study. Data were expressed in plasma equivalent units (PEU) where standard human 
plasma represents 1 PEU/mL. Data were represented as scatter plots (A & B) with mean bars (n= 4-6) and 
analyzed with one-way ANOVA followed by Bonferroni post hoc test *p < 0.05 and n.s. indicates no 
significance. WT: Wild-type mice; FSAP-/-: FSAP knockout mice. C.artery model: Carotid artery model; 
IVC: Inferior vena cava; Col./Epi. model: Collagen/Epinephrine or pulmonary embolism model.  
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and FSAP activity was measured by  immunocapture assay (Borkham-Kamphorst et al., 
2013; Kanse et al., 2012b).  This assay was also used to confirm the genotype of the mice. 
The carotid artery thrombosis experiment did not show any changes in systemic FSAP 
activity levels in thrombotic WT littermates compared to non-thrombotic littermates. 
Whereas, collagen and epinephrine induced thromboembolism model showed reduced 
systemic FSAP activity levels in thrombotic WT mice compared to non-thrombotic mice 
(Fig. 4.6A). IVC thrombosis experiment did show reduced systemic FSAP activity level 
after unfractionated heparin treatment as compared to PBS treatment in WT mice but it 
was statistically insignificant (Fig. 4.6B). 
4.6. The role of TFPI in the in vivo effects of endogenous FSAP 
Our previous findings showed that TFPI was proteolytically cleaved and 
inactivated by FSAP in vitro (Kanse et al., 2012a). We thus further wanted to investigate 
if this was clinically reliable in vivo using mouse model. There are three types of TFPI 
isoforms in mice (α, β and γ), TFPIβ being the prime form in mouse adult tissue 
(Massberg et al., 2010). TFPIβ lacks the Kunitz-3 domain; as a result, the heparin- 
releasable pool of TFPI in mice is very small. Foremost, we showed that immune-
captured mouse FSAP from mouse plasma could inactivate recombinant mouse TFPIα 
(Fig 4.7A). We next investigated whether FSAP degrades TFPI during arterial thrombosis 
in vivo. Carotid thrombi were exclusively stained for mouse TFPI and intense staining 
was observed in FSAP-/- mice compared to WT littermates (Fig. 4.7B). In carotid artery 
tissue extracts (Fig. 4.8A) and Western blotting analysis of mouse plasma (Fig. 4.7C), we 
obtained only one TFPI band at 55 kDa in WT littermates as well as FSAP-/- mice. In 
mice plasma from FeCl3 carotid artery thrombosis as well as venous thrombosis, TFPI 
was unaffected in FSAP-/- mice compared to WT littermates (Fig. 4.7C, D). Carotid artery 
tissue extracts of WT and FSAP-/- mice showed no differences in TFPI content in vessels 
with thrombosis or without thrombosis (Fig. 4.8A). Application of unfractionated heparin 
tends to decrease the levels of plasma TFPI (Fig. 4.7D).  
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Figure 4.7. Endogenous TFPI in FSAP-/- mice: Mouse plasma FSAP was immune-captured using anti 
mouse FSAP antibody. (A) Recombinant mouse TFPI β was added and residual was measured (% activity 
of TFPI). (B) Frozen sections of carotid artery with thrombosis (5µm) were stained for TFPI in WT and 
FSAP-/- mice (n=3). TFPI in plasma of WT and FSAP-/- mice with (C) carotid artery thrombosis (D) venous 
thrombosis and (E) pulmonary thromboembolism were analyzed by Western blotting (n=4). Plasma from 
WT and FSAP-/- mice was compared with respect to ceruloplasmin (CP) (loading control). Bands were 
quantified and the intensity of the TFPI band is represented in arbitrary units (AU) in relation to the CP 
bands.  (D) mice of both strains were given PBS or unfractionated heparin (100 U/Kg body weight) 10 min 
before induction of thrombosis. Data were expressed as mean ± SD. *p<0.05, **p<0.01, ***p<0.001 and 
n.s. indicates not significant. C.artery thrombosis: Carotid artery thrombosis; IVC: Inferior vena cava; 
Col./Epi. model: Collagen/Epinephrine or pulmonary embolism model . 
 
 
 
 
 
 
	  34	  |	  P a g e 	  
	  
CHAPTER	  4:	  RESULTS	  	  
 
Figure 4.8: (A) TFPI in tissue extracts of carotid artery thrombi: Carotid artery thrombosis was 
induced by topical application of filter paper soaked in 10 % FeCl3 solution for 3 min (T; grey bars). 
Contralateral vessels were used as controls (N; white bars). Thrombi/ vessels were collected and TFPI was 
analyzed by western blot (n=4). (B) Reduced venous thrombus formation: Venous thrombosis was 
induced by applying filter paper soaked in 5 % FeCl3 topically onto the IVC for 3 min. Thrombus vessels 
were collected and the vessel TFPI was measured by western blot (n=4). (C) Pulmonary embolism: Lungs 
from pulmonary embolism model were analysed for TFPI by western blotting (n=4). Data were expressed 
as mean ± SD. *p<0.05, **p<0.01 and n.s. indicates not significant. C.artery thrombosis: Carotid artery 
thrombosis; IVC: Inferior vena cava.  
  
These findings were further confirmed by the IVC tissue extracts i.e. TFPI and levels 
were determined by Western blotting. Unfractionated heparin treatment followed by IVC 
induced vessels displayed significantly higher TFPI (Fig. 4.8B) compared to PBS treated 
(control) group. In the collagen/epinephrine induced pulmonary thromboembolism 
model, the plasma TFPI in FSAP-/- mice was 1.8-fold higher than WT littermates 
signifying that a more systemic change in the thrombosis status is required to observe the 
effect of endogenous FSAP on TFPI (Fig. 4.7E). Similarly, lungs from 
collagen/epinephrine treated FSAP-/-mice showed significantly high TFPI (Fig. 4.9C). 
Ceruloplasmin and β actin were used as loading controls and respective plasma FSAP 
level was measured to confirm the lack of endogenous circulating FSAP in the knockout 
mice (Fig. 4.7).  
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Figure 4.9: Status of TFPI in plasma of mice from the different thrombosis model: Mouse plasma from 
WT and FSAP-/- mice subjected to FeCl3 induced carotid artery thrombosis, collagen/epinephrine induced 
pulmonary embolism and IVC thrombosis models were analyzed for TFPI by functional assay. Data were 
expressed in mean bars (n=7 to 10). *p<0.05, **p<0.01 and n.s. indicates not significant. Experiment 
performed by Michael Etscheid at Paul Erlich Institute, Germany. C.artery thrombosis: Carotid artery 
thrombosis; IVC: Inferior vena cava.  
TFPI activity was also measured in the mice plasma using a functional assay that 
measures FXa generation in TFPI-deficient plasma in a TF-dependent manner. In the 
localized models of arterial (Fig. 4.9A) and venous thrombosis (Fig. 4.9B) there were no 
differences between TFPI levels but in the systemic thrombosis (Fig. 4.9C) model, TFPI 
levels were higher in FSAP-/- mice as shown by the functional assay (Fig. 4.9A-C) which 
correlated well with the Western blot analysis (Fig. 4.7). Thus above study results 
represented that there was an association between lack of FSAP and higher circulating 
TFPI thereby showing that endogenous FSAP can regulate TFPI levels in vivo. 
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4.7.The role of active TFPI in the in vivo effects of endogenous FSAP 
 To further strengthen our hypothesis, active TFPI was also investigated by ligand 
blotting which relies on the binding of biotinylated FXa to active TFPI. The plasma from 
all the three mice thrombosis models were adopted for the ligand blotting to detect active 
circulating TFPI. 
 
Figure 4.10: Endogenous active TFPI in FSAP-/- mice: Active TFPI in plasma of WT and FSAP-/- mice 
with (A) carotid artery thrombosis (B) venous thrombosis and (C) pulmonary thromboembolism were 
analyzed by western blotting (n=4). Plasma from WT and FSAP-/- mice was compared with respect to 
ceruloplasmin (CP) (loading control). Bands were quantified and the intensity of the TFPI band is 
represented in arbitrary units (AU) in relation to the CP bands.  (D) mice of both strains were given PBS or 
unfractionated heparin (100 U/Kg body weight) 10 min before induction of thrombosis. Data were 
expressed as mean ± SD *p<0.05 and n.s. indicates not significant. C.artery thrombosis: Carotid artery 
thrombosis; IVC: Inferior vena cava. 
 
In the localized models of FeCl3 induced arterial (Fig. 4.10A) and venous thrombosis 
(Fig. 4.10B) there were no differences between TFPI levels but in the 
collagen/epinephrine induced systemic thrombosis (Fig. 4.10C) model, TFPI levels were 
higher in FSAP-/- mice as revealed by the functional assay method (Fig. 4.9A-C) which 
correlated well with the Western blot analysis (Fig. 4.7). In summation, the data obtained 
from the present study, clearly provided evidence that there is an association between a 
lack of FSAP and higher circulating active TFPI levels in vivo. 
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4.8 The role of FVII activation in the in vivo effects of endogenous FSAP 
While FVII was initially proposed to be a substrate for FSAP, we also investigated both 
FVII and FVIIa levels in the plasma (Fig. 4.11). Since we were particularly interested in 
 
Figure 4.11: Status of extrinsic pathway factors in plasma of mice from the different thrombosis 
model: Mouse plasma from WT and FSAP-/- mice subjected to FeCl3 induced carotid artery thrombosis 
(Row A), collagen/epinephrine induced pulmonary embolism (Row B) and IVC thrombosis (Row C) were 
analyzed for TFPI, FVII, FVIIa and FVIIa/FVII ratio. Data were expressed in mean bars (n=7 to 10). 
*p<0.05, **p<0.01 and n.s. indicates not significant. Experiment performed by Michael Etscheid at Paul 
Erlich Institute, Germany. C.artery thrombosis: Carotid artery thrombosis; IVC: Inferior vena cava. 
 
the question whether FSAP activates FVII, we also computed the ratio of FVIIa/ FVII to 
minimize the effect of deviations in the individual mice. In the venous thrombosis as well 
as the pulmonary thromboembolism model, FSAP-/- mice had lower levels of FVIIa/ FVII 
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(Fig. 4.11B &C). In the experiments where unfractionated heparin was given to the mice 
prior to the induction of venous thrombosis, no FVIIa levels could be measured due to the 
interference of heparin in the assay (Fig. 4.11C). Hence, we could confirm that activation 
of endogenous FVII is a function of FSAP and this could be observed in the local 
thrombosis models as well as in the systemic thrombosis model. 
4.9. Effect of endogenous FSAP on plasminogen and its activators 
Romisch and colleagues have shown that FSAP could activate pro-uPA to uPA  
 
Figure 4.12: Endogenous uPA activity in FSAP-/- mice: Plasminogen activation was determined by in 
situ zymography. Fresh frozen unfixed sections of vessels with thrombi for WT and FSAP-/- mice were 
overlaid with a mixture containing plasminogen, and quenched fluorescent BODIPY FL casein E6638 and 
incubated at 37˚C. Activation of plasminogen was indicated by the development of green fluorescence. 
Plasminogen activation in plasma of mice with carotid artery thrombosis (B), venous thrombosis (C) and 
pulmonary thromboembolism (D) were determined by gel-based casein zymography in the presence of 
plasminogen. Activation of plasminogen is indicated by dark lysis bands of either 45 kDa which is due to 
uPA or 65 kDa which is due to tPA. Both strains (C) of mice were given PBS or unfractionated heparin 
(100 U/Kg body weight) 10 min before induction of thrombosis. Plasma from WT and FSAP-/- mice was 
compared with respect to ceruloplasmin (CP) (loading control). Bands were quantified and the intensity of 
the TFPI band is represented in arbitrary units (AU) in relation to the CP bands. Data were expressed in 
mean ± SD (n=4). *p<0.05 and n.s. indicates not significant. C.artery thrombosis: Carotid artery 
thrombosis; IVC: Inferior vena cava 
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and thereby promote fibrinolysis in vitro (Romisch, 2002). So the differences in plasma 
fibrinolytic activity between WT and FSAP-/- mice were investigated using casein 
zymography.  In situ zymography showed that there was higher plasminogen activity in 
thrombi of FSAP-/- mice compared to WT littermates (Fig. 4.12A). Moreover, we also 
observed higher uPA levels in the thrombus of FSAP-/- mice. This activity was due to 
uPA since it was completely inhibited by the uPA inhibitor amiloride (Luikart et al., 
2002). Plasma from WT and FSAP-/- mice showed no significant differences in uPA 
activity in the carotid and venous thrombosis models but was increased about 2.4-fold in 
the collagen/epinephrine induced pulmonary thromboembolism model. In the same 
experiment we did not observe any changes in tPA activity (Fig. 4.12B-D). Plasma 
ceruloplasmin level was determined to calculate the normalized levels of uPA and tPA. 
Plasminogen levels, measured at the protein level by  
 
Figure 4.13: Plasminogen levels in FSAP-/- mice: Plasminogen in plasma of WT and FSAP-/- mice with 
(A) carotid artery thrombosis (B) venous thrombosis and (C) pulmonary thromboembolism were analyzed 
by Western blotting (n=4). Plasma from WT and FSAP-/- mice was compared with respect to ceruloplasmin 
(CP) (loading control). Bands were quantified and the intensity of the plasminogen band is represented in 
arbitrary units (AU) in relation to the CP bands. Data were expressed in mean ± SD. *p<0.05 and n.s. 
indicates not significant. C.artery thrombosis: Carotid artery thrombosis; IVC: Inferior vena cava. 
Western blotting showed no differences in both strains of mice in all of the three mouse 
model experiments (Fig. 4.13). Thus, contrary to our expectations we found that a lack of 
endogenous FSAP is associated with increased uPA activity, which in turn promotes 
fibrinolysis. 
 
	  40	  |	  P a g e 	  
	  
CHAPTER	  4:	  RESULTS	  	  
4.10. The effect of exogenously applied FSAP in vivo 
While the lack of endogenous FSAP influenced the outcome of thrombosis and 
haemostasis, we also investigated the consequences of applying exogenous FSAP 
 
Figure 4.14: Thrombosis in FSAP-/- mice reconstituted with exogenous FSAP: (A) human FSAP (1.2 
mg/Kg body weight) or HE (control buffer) was applied intravenously in WT and FSAP-/- mice before 15 
min before FeCl3-induced injury was performed. The scatter plot shows time to occlusion (TTO) in WT and 
FSAP-/- (n=8) mice. Data were represented as percentage blocks. (B) At the end of the experiment plasma 
was collected and analyzed by Western blotting for TFPI in WT (n=3) and FSAP-/- (n=3) mice. FSAP and 
CP were used as loading control as well as genotype control. (C) Active (ac) TFPI was measured by  
biotinylated FXa ligand blotting for active TFPI in WT (n=3) and FSAP-/- (n=3) mice. (D) Plasminogen 
activation in FSAP treated plasma was analyzed by gel based casein zymography in the presence of 
plasminogen. Activation of plasminogen is indicated by dark lysis uPA band at 45 kDa. Plasma from WT 
and FSAP-/- mice was compared with respective ceruloplasmin (CP) bands. Data were expressed in mean ± 
SD. *p<0.05, **p<0.01 and n.s. indicates not significant. C.artery thrombosis: Carotid artery thrombosis. 
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 (1.2 µg/kg, intravenously) in mouse. Elevated plasma FSAP levels were reached in mice 
with exogenously applied FSAP (Fig. 4.14A) and  
  
Figure 4.15: Status of extrinsic pathway factors in plasma of mice reconstituted with exogenous 
FSAP: Mouse plasma from WT and FSAP-/- mice subjected to FeCl3-induced carotid artery thrombosis was 
analyzed for TFPI (A), FVII (B), FVIIa (C) and FVIIa/FVII ratio (D). Data were expressed in mean bars 
(n=7 to 10). *p<0.05, n.s. indicates not significant. Experiment performed by Michael Etscheid at Paul 
Erlich Institute, Germany. C.artery thrombosis: Carotid artery thrombosis. 
 
a 2-fold increase was seen when compared to normal WT levels in FSAP-/- mice and 3.5-
fold in WT mice after application of exogenous FSAP (Fig. 4.14 A). In WT mice the 
application of exogenous FSAP did not alter the occlusion times rather it shortened it but 
this was not statistically significant. In FSAP-/- mice there was no occlusion in 37% of HE 
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buffer treated mice whereas after intravenous FSAP application all mice showed 
occlusion (Fig. 4.14A).  
 
Figure 4.16: FSAP activity assay and Plasminogen level: FSAP activity (A) was measured in plasma 
samples from mice reconstituted with exogenous FSAP. Data were expressed in plasma equivalent units 
(PEU) whereby standard human plasma represent 1 PEU/ml. Data were represented as scatter plots with 
mean bars (n=5-7). Plasminogen levels in FSAP-/- mice: Plasminogen in plasma (B) of WT and FSAP-/- 
mice reconstituted with exogenous FSAP followed by carotid artery thrombosis was analyzed by Western 
blotting (n=3). Plasma from WT and FSAP-/- mice was compared with respect to ceruloplasmin (CP) 
(loading control). Bands were quantified and the intensity of the plasminogen band was represented in 
arbitrary units (AU) in relation to the CP bands. Data were expressed in mean ± SD and analyzed with    
one-way ANOVA followed by Bonferroni Post hoc test *p < 0.05, ** p<0.01 and n.s. indicates no 
significant. 
 
Western blot analysis demonstrated that plasma TFPI decreased after application of 
exogenous FSAP and the decrease was more prominent in WT mice compared to FSAP-/- 
mice (Fig. 4.14B). Active TFPI was measured by ligand blotting which relies on the 
binding of biotinylated FXa to active TFPI by Western blotting. This quantitative analysis 
further confirmed that exogenous FSAP decreased TFPI in WT littermates but there were 
no significant differences between WT and FSAP-/- mice (Fig. 4.14C). Thus, exogenously 
applied FSAP also decreased TFPI activity in plasma in WT littermates but the decrease 
was not significant. We also measured FVII, FVIIa and the FVIIa/FVII ratio through 
functional assays in plasma. The FVII, FVIIa and the FVIIa/FVII ratio was not altered 
with exogenous FSAP (Fig. 4.15A-D) in WT littermates and FSAP-/- mice. uPA activity 
in the plasma of FSAP-/- mice was measured through casein zymography and it was high 
in FSAP treated groups compared to HE treated group. FSAP activity assay also 
performed in this model mouse plasma and showed the successful tail vein injection of 
FSAP (Fig. 4.16A). In addition, we measured the plasminogen level in FSAP treated 
	  43	  |	  P a g e 	  
	  
CHAPTER	  4:	  RESULTS	  	  
groups and we did not find any influence of exogenous FSAP on plasminogen level (Fig. 
4.16B). Thus, reconstitution of exogenous FSAP reversed the phenotype of the FSAP-/- 
mice and this could be associated with the decrease in TFPI but not activation of FVIIa or 
uPA. 
4.11. Physiological status of coagulation factors in WT and FSAP-/- mice 
 In the above thrombosis experiments we have demonstrated that lack of endogenous 
FSAP leads to an alteration in thrombosis and haemostasis in vivo. Although FVII and  
 
Figure 4.17: Normal plasma parameters in WT and FSAP-/- mice: (A) Coagulation factors were 
measured in the plasma of WT and FSAP-/- mice (n=10) Data were expressed in mean ± SD. *p<0.05 and 
n.s. indicates not significant. (Michael Etscheid at Paul Erlich Institute, Germany performed clotting 
assays). 
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TFPI have been considered as potential candidates that are regulated by FSAP we also 
screened for any other changes in whole blood, plasma and platelets that may account for 
the observed phenotype. Concentration of FII, FV, FVII, FX, FVIII, FIX, FXI, FXII and 
plasma kallikrein (Döttl K, 1936) was measured in mouse plasma using human deficient 
plasma and appropriate human standards. No differences were observed in these factors 
between the WT and FSAP-/- mice (Fig. 4.17A). 
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5. Discussion  
Vascular injury or damage results in the activation of plasma circulating factor 
VII, which in turn activates the extrinsic pathway system via interaction with cellular TF. 
Many reports suggest the source of TF to be damaged subendothelial cells and its activity 
is inhibited by TFPI. Loss of TFPI, TF, FVII or thrombin leads to embryonic lethality, 
which demonstrates their critical significance in thrombosis, haemostasis and embryonic 
development. Our results with the FSAP-/- mice indicate that endogenous FSAP is a 
subtle modifier of these coagulation pathways. Our study showed that FSAP functions 
through a mechanism, which is common to both thrombosis as well as haemostasis in 
vivo. The deletion of endogenous FSAP leads to comparatively higher levels of TFPI and. 
This increase in TFPI decelerates the extrinsic pathway. Thus the lack of FSAP prolongs 
clotting time and leads to the formation of unstable clots in vivo.   
5.1. FSAP and haemostasis  
The tail-bleeding assay provides a measure of the physiological “response to 
injury” coagulation in vivo (Kung et al., 1998) and is sensitive to different levels of 
coagulation factors (Dejana et al., 1979; Gailani et al., 1997). However, complete tail 
transection could lead to opening up of the both lateral veins as well as central artery 
which in turn may lead to variations in the bleeding time. However, it is unclear how the 
outcomes of the tail-bleeding assay can be extrapolated to humans (Mackman, 2004). 
Data suggests that, initial bleeding time in FSAP-/- mice is similar to that of WT 
littermates. However, some FSAP-/- mice were bleeding until 12 min. Thus in-comparison 
with WT littermates, re-bleeding incidence and total blood loss were high in these mice, 
thereby revealing that FSAP influences the normal primary haemostatic function and may 
lead to enhanced re-bleeding events by destabilization of clot.    
5.2. Endogenous/exogenous FSAP and stability of thrombosis  
Numerous experimental mouse models as well as different induction methods 
have been used so for by researchers to study thrombosis in vivo (Sachs and Nieswandt, 
2007). One method to initiate endothelial damage is through photochemical substances 
like Rose Bengal (Westrick et al., 2007) and Hematoporphyrin (Rauova, 2012), which 
when injected into the body, rapidly accumulates on the endothelial surfaces. These 
accumulated photochemical substances are then exposed to green light (540 nm) which 
leads to a photochemical reaction at the targeted site resulting in the production of free 
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radicals/oxygen species that damage the endothelial cells around the site and induce 
thrombosis (Kikuchi et al., 1998). Another model utilizes lasers to target the vessel walls 
and damage it.   
The procedure that has been most widely used to induce vascular injury is the 
direct FeCl3 application on the arterial vessel surface to induce endothelial damage 
followed by the formation of a platelet rich thrombus. Although the exact mechanism by 
which thrombus initiation by FeCl3 is not clear, it has been shown that the morphology of 
the thrombi is similar to those found in humans (Farrehi et al., 1998). The FeCl3 induced 
vascular injury has been performed on major arteries and veins like carotid and femoral 
arteries, jugular veins, and minor arterioles and venules like mesenteric and cremasteric 
arterioles and venules in mice, rats, guinea pigs and rabbits (Chen et al., 2011; Eckly et 
al., 2011; Konstantinides et al., 2001; Leadley et al., 1999; Li et al., 2010; Marsh Lyle et 
al., 1998). Although this model offers many advantages, there are some limitations. The 
destructive oxidative stress induced by FeCl3 may denature or alter circulating and 
membrane-bound proteins. Use of occlusion time as an endpoint of thrombosis 
experiments is somewhat crude (Ghosh et al., 2008; Owens et al., 2011). There are many 
reports on the use of 10% to 15% FeCl3 for arterial thrombosis. In our present study, 
optimized concentration of FeCl3 (10%) was used for experimental procedures. However, 
in the venous thrombosis model, an optimized model with 3.5% FeCl3 was used to trigger 
the vascular injury, while retaining good sensitivity to heparin.  
Although tissue factor (TF) initiates thrombosis in most of these models, the 
source of cellular TF varies depending on the nature of injury. If the integrity of the 
vessel wall is disturbed, blood comes in contact with the TF expressing sub-endothelium 
cells (Kretz et al., 2010). Regardless of the source of TF, thrombosis will occur provided 
there is sufficient TF to overcome the inhibitory effects of TFPI (van 't Veer and Mann, 
1997). FeCl3 causes denudation of the endothelium, (Wang and Xu, 2005) and exposes 
the sub-endothelium, including collagen (Kurz et al., 1990). Platelet accumulation after 
FeCl3 exposure to the vascular wall is dependent on both collagen and thrombin. 
Collagen provides a TF independent mechanism of thrombus formation (Kretz et al., 
2010). This model is simple and sensitive to both	  anticoagulant and anti-platelets drugs.  
Three different groups, using different vascular beds, and methods of analysis, 
replicated the in vivo results with FSAP-/- mice independently. Although a heterogeneity 
response was seen in case of FSAP-/- mice, this cannot be attributed to the age or sex of 
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these mice. Moreover, the mice used were backcrossed for 10 generations with the 
C57BL/6J background and littermate controls from heterozygous crosses and maintained 
in the same room. Thus the obvious factors were excluded and the origin of this 
heterogeneity needs to be further investigated. Nevertheless, we have shown here that the 
mice reconstituted with human FSAP can reverse the phenotype in FSAP-/- mice. Through 
the activity assay, we observed that circulating FSAP level in human and mouse plasma 
are almost equal. Reconstitution of human FSAP in FSAP-/- mice followed by carotid 
artery thrombosis restored the arterial thrombosis to the pattern observed in WT mice. 
Furthermore, WT mice that received the human FSAP showed faster occlusion than the 
HE buffer treated WT mice. These results confirmed that FSAP support the 
procoagulation process.  
Thrombus firmness mostly depends on the second wave mediators, including 
ADP and TXA2. They, together with epinephrine, share the property of binding G-protein 
coupled receptors. These GPCRs are known to act in concert to achieve full platelet 
activation by cAMP suppression, increase calcium ions concentration and phospholipase 
activation (Pozgajova et al., 2006). Epinephrine alone is not enough to promote platelet 
structure change, aggregation, or αIIbβ3 activation (Lanza and Cazenave, 1985; 
Nieswandt et al., 2001), but it potentiates different responses with collagen and thereby 
contributes to platelet activation in vitro as well as in vivo (Pozgajova et al., 2006). The 
activated platelets in turn increase TXA2, leading to stronger platelet aggregation. In our 
study, FSAP-/- mice showed more resistance to collagen/epinephrine induced pulmonary 
thromboembolism compared to WT littermates in vivo. These finding implies that FSAP 
is required for stable platelet plug formation. This protective effect in FSAP-/- mice may 
be due to the high TFPI which disturbs the coagulation process in vivo.  
5.3. Endogenous/exogenous FSAP and FVII activation 
Factor VII is produced in the liver and circulates in the plasma where it binds to 
tissue factor (TF), an integral membrane protein, which is exposed to the blood 
circulation upon vessel injury. This TF:VIIa complex in turn activates FXa that leads to 
prothrombin activation. However, this complex is inhibited by TFPI. Factor VII 
activating protease was so named, because FVII was identified as the initial substrate 
(Romisch, 2002). Recent, studies on human plasma proposed that activation of FVII was 
much weaker than inactivation of TFPI (Kanse et al., 2012a). In order to analyze this 
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concept in vivo, we also measured circulating factor like FVII, FVIIa and the ratio of 
FVIIa/FVII. The results showed that the FVII antigen level in plasma from WT and 
FSAP-/- mice were normal. However, there was a consumption of FSAP in the 
thromboembolism model which resulted in increased residual FVII levels in FSAP-/- mice 
compared to WT mice. This higher the residual FVII were correlated with higher the 
TFPI and ultimately leads to lower the coagulation in FSAP-/- mice.  Interestingly, 
addition of exogenous FSAP into the FSAP-/- mice did not alter the levels of FVII as well 
as FVIIa. This result is well correlating with the recent in vitro study that FVII might not 
be a direct physiologically relevant substrate for FSAP:   
5.4.Endogenous/exogenous FSAP and TFPI 
The primary inhibitor of the TF pathway is TFPI, which inactivates FXa and 
FVIIa immediately following their generation. Alternative splicing leads to the generation 
of 2 main isoforms called TFPIα and TFPIβ. TFPIα has all 3 Kunitz domains as well as 
the C-terminal heparin-binding region whereas TFPIβ has only the first 2 Kunitz domains 
and is linked to a glycosylphosphatidylinositol anchor that restricts it to the surface of the 
plasma membrane.  TFPIα is produced by platelets and TFPIβ by endothelial cells (Mast, 
2011). A large majority of the TFPI in an adult mouse is TFPIβ, which is more resistant 
to release by heparin. The activity of TFPI is regulated by a number of proteases such as 
plasmin, neutrophil elastase (Broze and Girard, 2012; Massberg et al., 2010) and FSAP 
(Kanse et al., 2012a), which cleave specific sites within the molecule. Our previous 
studies have shown that TFPIα is a better substrate than TFPIβ in vitro but on endothelial 
cells FSAP is capable of cleaving TFPIβ (Kanse et al., 2012a). Although the specific 
functions of different forms of TFPI are not completely determined, the full-length TFPI 
shows a strong anticoagulant effect than the truncated form (Dahm et al., 2006; Lindahl et 
al., 1991).    
The assay of TFPI is complex, as in vivo the protein molecule is present in various 
intravascular pools and is heteregenous in its structure. Degree of lipidation and 
truncation influence the antigen detection as well as anticoagulant effect. Antigen assay 
and chromogenic assay are used to detect total TFPI. TFPI activity assay is based on the 
ability of TFPI in the sample to inhibit TF:FVIIa catalytic activity, in presence of FXa 
(Bendz et al., 2000). In this study the levels of TFPI were measured using three different 
methods and showed an excellent correlation confirming the reliability of these 
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conclusions. TFPI was measured using western blot; ligand blot with FXa, which binds 
active TFPI; and a TFPI activity assay based on measuring FXa generation. We also 
measured TFPI in all the models plasma as well as in thrombi by western blotting and 
immunofluorescence analysis.  
In the collagen/epinephrine model of pulmonary thromboembolism, where large-
scale systemic changes would be expected, higher levels of TFPI were observed in 
plasma of FSAP-/- mice using all three methods. Also the lung homogenates from this 
model showed significantly higher TFPI in FSAP-/- mice.  In control mice as well as when 
thrombosis (induced locally with FeCl3) vessels showed no differences in plasma TFPI. 
Although the immunostaining of TFPI showed higher staining in FSAP-/- mice carotid 
artery thrombi the same was not observed by western blotting, which is a more 
quantitative technique. Thus, our results confirm that endogenous FSAP is able to inhibit 
TFPI in vivo and thus promote the pro-coagulation through up regulation of the extrinsic 
pathway.  
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6. CONCLUSION AND FUTURE PROSPECTS  
6.1. CONCLUSION 
While deficiency of FSAP in human is unidentified so far, carriers of MI-SNP have 
lower proteolytic activity. A few clinical studies have proposed an association between 
MI-SNP and venous thrombosis (Ahmad-Nejad et al., 2012b; Hoppe et al., 2005). 
Whereas on the other hand, other studies did not find such an association (Franchi et al., 
2006; Gulesserian et al., 2006; Pecheniuk et al., 2008; van Minkelen et al., 2005; 
Weisbach et al., 2007). In our thrombosis studies with FSAP-/- mice, we observe that the 
deficiency of FSAP activity or loss of FSAP activity, as like in the MI-SNP carriers, 
would lead to an anti-thrombotic phenotype due to the TFPI inhibition by FSAP and we 
speculate that there is no correlation with thrombosis and MI-SNP in vivo.  
The findings of the present study are as follows: 
1. Tail-bleeding assay model of haemostasis showed that FSAP-/- mice had 
significantly higher blood loss and re-bleeding incidence. It confirms that FSAP is 
required for the normal haemostasis process.  
 
2. Thrombosis models (FeCl3-induced carotid artery model, mesenteric arteriole 
model, venous thrombosis model and pulmonary embolism model) showed that 
FSAP-/- mice were protected against thrombosis in vivo. 
 
3. Functional assays clearly showed that FVII might not be a physiologically 
relevant substrate for FSAP 
 
4. Plasma and tissue samples were assessed for TFPI measurement using various 
methods (function assays, western blotting, ligand blotting, immuno-capturing) 
and the outcome clearly indicates that FSAP inhibits TFPI in vivo. 
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Figure 6.1: Role of exogenous human FSAP in vivo (proposed model): FSAP activation in vivo is due to 
the release of nuecleosomes and histones in response to vascular injury. This activation leads to up- 
regulation of extrinsic pathway by inhibition of TFPI (1). Similarly, the exogenous FSAP (2) injection also 
showed that the FSAP inhibits TFPI.  
 
In light of our results we predict that a loss of FSAP activity, as in carriers of MI-SNP, is 
likely to protect against thrombosis. However, species-specific differences in the actions 
of FSAP cannot be excluded at this stage. We suggest that FSAP activation in vivo is due 
to the release of nucleosomes and histones in response to vascular injury. This hypothesis 
mirrors well with the study that DNAse treatment or blocking histones reduces thrombus 
incidences (Esmon, 2012; Fuchs et al., 2012). Our mice models revealed that the 
endogenous FSAP plays a key role in extrinsic coagulation pathway via inhibition of 
TFPI in vivo (Fig. 6.1). The delayed coagulation seen in our case (FSAP-/- mice) might be 
due to the influence of tissue factor pathway inhibitor (TFPI) on extrinsic system. Thus, 
FSAP could be a cofounding factor in thrombosis and haemostasis in vivo. 
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SUMMARY	  
SUMMARY 
Factor VII activating protease (FSAP), a serine protease produced in the liver (plasma 
conc.12 µg/mL) has been associated with cardiovascular diseases. In vitro studies 
revealed that FSAP has a dual function in the coagulation system via inhibition of tissue 
factor pathway inhibitor (TFPI) and activation of pro-urokinase (pro-uPA). Even though 
functional polymorphism in the FSAP gene is linked with cardiovascular diseases, due to 
contradictory clinical observations as well as its dual role in the coagulation system in 
vitro, the real function and mechanistic aspects of FSAP is ambiguous. To identify the 
actual function of FSAP in thrombosis and haemostasis, we characterized the FSAP 
deficient mice using various in vivo and ex-vivo mouse models. Our results showed that in 
pulmonary thromboembolism model FSAP-/- mice had a significantly higher survival than 
WT littermates (p < 0.01). The carotid artery injury as well as mesenteric arteriole models 
revealed that the occlusion time was significantly increased in FSAP-/- mice (p < 0.01). 
Partial venous thrombosis (PVT) showed a trend in the reduction of total thrombus 
content and thrombus weight in FSAP-/- mice. Western blotting analysis of plasma 
samples as well as immunohistochemical analysis of thrombotic carotid arteries and lung 
tissue extracts showed a slightly increased TFPI expression in FSAP-/- mice when 
compared to the WT littermates. In situ and gel-based casein zymography showed that 
FSAP-/- mice had more uPA than the WT littermates. Plasma samples from all these 
models did not show any influence of plasminogen levels. In vitro analysis of FSAP on 
platelet TFPI demonstrated that FSAP could inhibit not only the circulating β form of 
TFPI but also the platelet derived α form of TFPI. Tail-bleeding assay revealed that more 
than 80% of FSAP-/-mice showed re-bleeding incidences compared to WT littermate 
controls. The clinical relevance of Marburg-I polymorphism is not well understood 
because of contradictory observations in various studies. Interestingly, our mice models 
revealed that the endogenous FSAP plays a key role in extrinsic coagulation cascade via 
inhibition of TFPI.  
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ZUSAMMENFASUNG	  
ZUSAMMENFASUNG 
Die Faktor VII aktivierende Protease (FSAP), eine in der Leber synthetisierte 
Serinprotease (Plasmakonzentration: 12 µg/ mL), spielt eine Rolle bei kardiovaskulären 
Erkrankungen. In vitro Studien zeigten, dass FSAP eine duale Rolle in der Hämostase 
innehat. Einerseits wirkt FSAP prokuagolatorisch durch Hemmung des Gewebsfaktor-
Plasminogen Inhibitors(TFPI), andererseits fibrinolytisch durch Aktivierung der Prouro- 
kinase (pro-uPA). Obwohl der funktionale Polymorphismus des FSAP-Gens mit 
kardiovaskulären Erkrankungen verbunden ist, bleibt die Funktion und Wirkungsweise 
von FSAP aufgrund widersprüchlicher klinischer Untersuchungen wie auch seiner dualen 
Rolle im Hämostasesystem, unklar.  Zur Aufklärung der Funktion von FSAP in Hinsicht 
auf Thrombose und Hämostase wurden FSAP-defiziente Mäuse in verschiedenen in vivo 
und ex vivo Modellen getestet. Unsere Ergebnisse  zeigten, dass FSAP-/- Mäuse in einem 
Lungen-Thrombose-Embolie-Modell eine signifikant höhere Überlebensrate aufwiesen 
als WT-Mäuse (p < 0.01).  Bei  Verletzung der Karotis-Arterie oder der Mesenterial-
arteriole war die Okklusionszeit bei FSAP-/- Mäusen signifikant erhöht (p < 0.01).  Eine 
partiale Venenthrombose (PVT) zeigte tendenziell eine Verringerung des Thrombus in 
Größe und Gewicht. Westernblot-Analysen von Plasmaproben wie auch 
immunohistochemische Untersuchungen an thrombotischen Karotis-Arterien und 
Lungenextrakten ergaben einen leichten Anstieg der TFPI-Expression bei FSAP-/- 
Mäusen verglichen mit WT-Mäusen. In der In-situ-Zymographie sowie Gel basierenden 
Kasein-Zymographie zeigten FSAP-/- Mäuse gegnüber WT-Mäusen höhere uPA-Spiegel. 
Plasmaproben aus allen Modellen zeigten keinen Einfluss von FSAP auf die 
Plasminogenkonzentration. In vitro Untersuchungen an Plättchen-TFPI zeigten, dass 
FSAP nicht nur  die zirkulierende ß-Form von TFPI, sondern auch  die platelet-derived α-
Form von TFPI hemmt. Bei Messungen der Blutungszeit durch Verletzung des 
Schwanzes der Mäuse  neigten mehr als 80% der FSAP-/- Mäuse zu wiederholtem Bluten 
gegenüber WT-Mäusen. Die klinische Relevanz des Maburg I Polymorphismus ist 
aufgrund der widersprüchlichen Beobachtungen an Venenthrombose-Modellen wenig 
verstanden. Unsere Mausmodelle zeigten, dass endogenes FSAP eine Schlüsselrolle bei 
der extrinsischen Blutgerinnungskaskade durch Hemmung von TFPI innehat.  
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ANNEXURE:	  REAGENTS	  
REAGENTS 
PRODUCT COMPANY 
2-Mercaptoethanol Sigma-Aldrich Chemie, Munich, Germany 
Acetone 99,8% Merck, Darmstadt, Germany 
ADP Sigma (Deisenhofen, Germany) 
Agarose Sigma Life Science, USA 
Amiloride Sigma-Aldrich Chemie, Steinheim, Germany 
APS Roth (Karlsruhe, Germany) 
Aqua ad iniectabilia (H2O dd) Baxter, Unterschleißheim, Germany 
Arginine Sigma-Aldrich Chemie, Munich, Germany 
Beta-mercaptoethanol Roth (Karlsruhe, Germany) 
Bovine serum albumine (BSA) Sigma-Aldrich Chemie, Munich, Germany 
Calcium chloride Sigma-Aldrich Chemie, Munich, Germany 
Chromogenic substrate S1344 PNAPEP 1344, Haemochrom Diagnostica, France 
Collagen (Horm) NYCOMED, Germany 
Convulxin Alexis Biochemicals (San Diego, USA) 
DAPI Linaris, Wertheim, Germany 
DQ-casein Molecular Probes, Leiden, The Netherlands 
Dylight 488 Pierce (Rockford, IL, USA) 
Eosin Y Disoldium salt Sigma-Aldrich Chemie, Munich, Germany 
EDTA Carl ROTH, Germany 
Epinephrine Adrenalin 1:100, JENAPHARM®, Germany 
Erythrocyte lysis buffer Biolegend, San Diego, CA, USA 
Ethanol Sigma-Aldrich, Germany 
Ferric chloride FeCl3. 6H2O, Fluka Chemie, Buchs, Switzerland 
Formalin solution (PFA) 3.7% Carl ROTH, Karlsruhe, Germany 
Glycerol Sigma-Aldrich Chemie, Munich, Germany 
Glycine Carl ROTH, Germany  
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ANNEXURE:	  REAGENTS	  
Hematoxylin solution Merck, Darmstadt, Germany 
Heparin Ratiopharm, Ulm, Germany 
Histofix 4 % (PFA) Carl ROTH, Karlsruhe, Germany 
Iso-propanol Merck, Darmstadt, Germany 
Lysine Sigma-Aldrich Chemie, Munich, Germany 
Methanol Merck, Darmstadt, Germany 
Penicillin / Streptomycin PAA Laboratories, Pasching, Austria 
Potassium chloride  Carl ROTH, Germany 
Skim milk powder Fluka Analytical, Buchs, Switzerland 
Sodium acetate Fluka Chemie, Buchs, Switzerland 
Sodium azide Sigma-Aldrich Chemie, Munich, Germany 
Sodium chloride 0.9% (NaCl) Carl ROTH, Germany 
Sodium citrate (3.8%) Carl ROTH, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Carl ROTH, Karlsruhe, Germany 
TEMED Carl ROTH, Karlsruhe, Germany 
Thrombin Roche Diagnostics (Mannheim) 
Tissue factor Siemens, Innovin 
Triton X-100 Sigma-Aldrich Chemie, Munich, Germany 
Tris Carl ROTH, Karlsruhe,Germany 
Trypan blue solution (0.4%) Sigma-Aldrich Chemie, Munich, Germany 
Tween 20 Sigma-Aldrich Chemie, Munich, Germany 
U46619 Alexis Biochemicals (San Diego, USA) 
Vectashield MM H 1000 Vector Laboratories, Burlington, CA, USA 
Zinc chloride Carl ROTH, Karlsruhe,Germany 
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ANNEXURE:	  SURGICALS	  
DRUGS USED FOR ANESTHESIA 
PRODUCT COMPANY 
Atropinsulfate-solution 0,5 mg/mL Fresenius Kabi, Bad Homburg, Germany 
Isoflurane Baxter, Unterschleißheim, Germany 
Ketamine 50 mg/mL Inresa, Freiburg, Germany 
Xylazine 2% Bayer, Leverkusen, Germany 
 
SURGERY MATERIALS 
PRODUCT COMPANY 
Butterfly perfusion set Micro Flow  
0,5 19 mm (24 Gau) 
Meditop/surgyplus, MALAYSIA 
Cover glass for slides Menzel, Braunschweig, Germany 
Parafilm® American National Can™, Neenah, WI, USA 
Pipettes 1000 / 200 / 100  / 10 / 2 Eppendorf, Wesseling-Betzdorf, Germany 
Safe Seal Microcentrifuge Tubes 0.65 
mL/2 mL 
Sorenson Bioscience, Inc., Salt Lake City, UT, USA 
Single-use syringe 1ml, Injekt F, 
Tuberkulin 
B. Braun, Melsungen, Germany 
Single-use syringe 5mL, Injekt Solo B. Braun, Melsungen, Germany 
Skin disinfection Softasept® B. Braun, Melsungen, Germany 
Sterile needle, 20 Gau, 0,9 70 mm Terumo Euope, Leuven, Belgium 
Sterile needle, 30 Gau, 0,3 13 mm Terumo Euope, Leuven, Belgium 
Sterile needle, BD Microlance ™ 26 
Gau, 0,45 13mm 
BD Drogheda, Ireland 
Tissue Tek OCT Compound 
Sakura Finetek Europe B.V., Zoeterwoude, The 
Netherlands 
Ultrasound gel Aquasonic 100™, Parker Labs 
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ANNEXURE:	  ANTIBODIES/PCR	  KITS	  
ANTIBODIES: WESTERN BLOTTING 
NAME SPECIES ISOTYPE 
WORKING 
DILUTION 
COMPANY 
TFPI Rabbit Polyclonal 1:5000 
Santa Cruz Biotech, 
Germany 
Fibrin (ogen) Rabbit/αHuman Polyclonal 1:10,000 DAKO, Denmark 
Plasminogen Rabbit/αHuman Polyclonal 1:10,000 DAKO, Denmark 
PAI-1 Rabbit Polyclonal 1:1000 
Molecular Innovation,  
Germany 
FSAP (ME) Rabbit Polyclonal 1:1000 
In-house preparation, Dr. 
Michael Etscheid, Langen 
Ceruloplasmin Rabbit/αHuman Polyclonal 1:10,000 DAKO, Denmark 
Β actin Rabbit Polyclonal 1:5,000 Cell Signaling, USA 
 
ANTIBODIES: IMMUNOFLUORESCENCE  
NAME SPECIES ISOTYPE 
WORKING 
DILUTION 
COMPANY 
TFPI Rabbit Polyclonal 1:100 Santa Cruz Biotech, Germany 
IgG Rabbit Polyclonal 1:100 Santa Cruz Biotech, Germany 
 
ACTIVITY ASSAY: IMMUNOFLUORESCENCE  
ASSAY KIT COMPANY 
In situ zymography 
EnzChek® Protease Assay Kit 
BODIPY FL E6638, Green 
Fluorescence 
Life Technologies, USA 
 
RNA/cDNA/RTPCR KITS 
PURPOSE KIT COMPANY 
RNA isolation GenElute, Miniprep Kit Sigma-Alderch, Germany 
cDNA synthesis 
GeneAmp Thermostable rTth reverse 
transcriptase 
Applied Biosystems, USA 
q-PCR SYBR-Green: SensiMix-HiROX Bioline, USA 
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ANNEXURE:	  BUFFERS	  
BUFFERS 
Acid-citrate-dextrose (ACD) buffer  
pH 4.5 
Trisodium citrate dehydrate  85 mM 
Citric acid anhydrous   65 mM 
Glucose anhydrous   110 mM 
Blocking solution for immunoblotting  
BSA or fat-free dry milk  5% 
in PBS or washing buffer (TBST) 
Coomassie staining solution  
Acetic acid    10%  
Methanol    40%  
Coomassie Brilliant blue  0.01% 
Coomassie destaining solution 
Glacial acetic acid   10% 
Methanol    30% 
Phosphate buffered saline (PBS), pH 7.14 
NaCl     137 mM 
KCl     2.7 mM 
KH2PO4    1.5 mM 
Na2HPO4    8 mM 
SDS sample buffer, 2X 
β Mercaptoethanol   10% 
TRIS buffer (1.25 M), pH 6.8 10% 
Glycerine   20% 
SDS     4% 
Bromophenolblue   0.02% 
Stripping buffer, pH 6.8 
β Mercaptoethanol  100 mM 
SDS    2% 
Tris HCI pH 6.7  62.5 mM 
Tris-buffered saline (TBS) 10X, pH 7.3 
Tris 250 mM   30 g 
NaCl 1.5 M   80 g 
KCl     2 g 
d.d.a    1 L      
Blotting buffer (Western blot) 
Tris 0.02M   12,125g 
Glycin 0.15M   56,250g 
Methanol     1L 
d.d.a    5L 
Tyrode´s buffer, pH 7.3  
NaCl    137 mM  
KCl     2.7 mM  
NaHCO3    12 mM  
NaH2PO4    0.43 mM 
CaCl2    1 mM  
MgCl2    1 mM  
HEPES    5 mM  
BSA     0.35%  
Glucose    0.1% 
Washing buffer (Western blot) 
Tween  20 in TBS, pH 7.2 0.1% 
Trenngel buffer, pH 8.8 
Tris/HCl 1.5 M  90.82 g 
10 % SDS (0.4%)  20 mL 
d.d.a    500 mL 
Sammelgel buffer, pH 6.8 
Tris/HCl 1 M   24.2 g 
10% SDS (0.4%)  8 mL 
d.d.a    200 mL 
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ANNEXURE:	  BUFFERS	  
FSAP activity: Coating buffer  
Na2CO3   15 mM 
NaHCO3   35 mM 
pH 9,0 
FSAP activity: Standard buffer  
Sodium Citrate  20mM 
NaCl2     150mM 
FSAP activity: Blocking buffer 
Standard buffer    20 mM 
BSA    2 % 
Arginin   100 mM 
FSAP activity: Dilution buffer 
Standard buffer    20 mM 
BSA    1% 
Tween 80   0.1% 
Heparin   1.57 mg/mL 
FSAP activity: Assay buffer -I 
TBS-T80   0.1% 
CaCl2    2 mM 
Heparin   20 µg/mL 
FSAP activity: Assay buffer -II 
TBS-T80   0.1% 
Pro uPA   10 µg/mL 
Gelatin zymography: Washing buffer 
(4X) 
1M Tris pH 7.6  30 mL 
200 mM CaCl2   30 mL 
10 mM ZnCl2   60 µL 
Triton X100   15 g  
Casein zymography: Washing buffer 
Triton X100   2. 5% 
d.d.a 
 
Casein zymography: Agarose 
Noble agarose   2. 5% 
d.d.a 
Gelatin zymography :Incubation buffer 
(4X) 
1M Tris pH 7.6  20 mL 
200 mM CaCl2   20 mL 
10 mM ZnCl2   40 µL 
Triton X100   4 g  
10% NaN3   4 mL 
Gelatin zymography: Lower gel (4X) 
Gelatin 2 %   3 mL 
Water    11.55 mL 
Trenngel buffer  7.5 mL 
Acryl amide   7.95 mL 
APS    0.2 mL 
TEMED   0.02 mL 
Western Blot: Trenngel gel (4X) 
 
Trenngel buffer  7.5 mL 
Acryl amide   10.05 mL 
Water    12.45 mL 
APS    0.2 mL 
TEMED   0.02 mL 
Western Blot: Sammel gel (4X) 
Sammel buffer  2.5 mL 
Acryl amide   1.65 mL 
Water    5.72 mL 
APS    0.1 mL 
TEMED   0.01 mL 
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